JP5910976B2 - 精神神経疾患又は悪性腫瘍に関する化合物及び医薬組成物 - Google Patents
精神神経疾患又は悪性腫瘍に関する化合物及び医薬組成物 Download PDFInfo
- Publication number
- JP5910976B2 JP5910976B2 JP2014528176A JP2014528176A JP5910976B2 JP 5910976 B2 JP5910976 B2 JP 5910976B2 JP 2014528176 A JP2014528176 A JP 2014528176A JP 2014528176 A JP2014528176 A JP 2014528176A JP 5910976 B2 JP5910976 B2 JP 5910976B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- mmol
- aromatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims description 186
- 201000011510 cancer Diseases 0.000 title claims description 83
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 43
- 208000012902 Nervous system disease Diseases 0.000 title description 2
- 125000003118 aryl group Chemical group 0.000 claims description 172
- 150000003839 salts Chemical class 0.000 claims description 81
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 48
- 208000035475 disorder Diseases 0.000 claims description 43
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 42
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 42
- 230000005764 inhibitory process Effects 0.000 claims description 41
- 125000001072 heteroaryl group Chemical group 0.000 claims description 40
- 230000002265 prevention Effects 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 35
- 125000005843 halogen group Chemical group 0.000 claims description 33
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 29
- 125000004429 atom Chemical group 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 14
- 125000003367 polycyclic group Chemical group 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 7
- 241000282412 Homo Species 0.000 claims description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 175
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 138
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 133
- 239000013065 commercial product Substances 0.000 description 131
- 235000019439 ethyl acetate Nutrition 0.000 description 78
- 238000005481 NMR spectroscopy Methods 0.000 description 68
- 239000000203 mixture Substances 0.000 description 67
- 239000007787 solid Substances 0.000 description 64
- -1 phosphate ester Chemical class 0.000 description 57
- 239000000651 prodrug Substances 0.000 description 55
- 229940002612 prodrug Drugs 0.000 description 55
- 230000015572 biosynthetic process Effects 0.000 description 53
- 239000000243 solution Substances 0.000 description 52
- 238000003786 synthesis reaction Methods 0.000 description 52
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 49
- 230000002829 reductive effect Effects 0.000 description 49
- 102000013498 tau Proteins Human genes 0.000 description 46
- 108010026424 tau Proteins Proteins 0.000 description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 38
- 239000012300 argon atmosphere Substances 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 238000004519 manufacturing process Methods 0.000 description 35
- 239000012044 organic layer Substances 0.000 description 33
- 230000002401 inhibitory effect Effects 0.000 description 32
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 30
- 229910052938 sodium sulfate Inorganic materials 0.000 description 30
- 235000011152 sodium sulphate Nutrition 0.000 description 30
- 239000000706 filtrate Substances 0.000 description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 25
- 238000001816 cooling Methods 0.000 description 24
- 238000011156 evaluation Methods 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 23
- 238000004440 column chromatography Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 20
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 20
- 230000026731 phosphorylation Effects 0.000 description 20
- 238000006366 phosphorylation reaction Methods 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 229940125782 compound 2 Drugs 0.000 description 16
- 230000009422 growth inhibiting effect Effects 0.000 description 16
- 238000010992 reflux Methods 0.000 description 15
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 description 14
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 description 14
- 239000013078 crystal Substances 0.000 description 14
- 230000009822 protein phosphorylation Effects 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 201000010374 Down Syndrome Diseases 0.000 description 13
- 206010044688 Trisomy 21 Diseases 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 12
- 210000004748 cultured cell Anatomy 0.000 description 12
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 12
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 11
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 11
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 11
- UVECLJDRPFNRRQ-UHFFFAOYSA-N ethyl trifluoromethanesulfonate Chemical compound CCOS(=O)(=O)C(F)(F)F UVECLJDRPFNRRQ-UHFFFAOYSA-N 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 102000001301 EGF receptor Human genes 0.000 description 10
- 108060006698 EGF receptor Proteins 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 229940125904 compound 1 Drugs 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000010792 warming Methods 0.000 description 10
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 239000011259 mixed solution Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 7
- 239000005695 Ammonium acetate Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 7
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 7
- 235000019257 ammonium acetate Nutrition 0.000 description 7
- 229940043376 ammonium acetate Drugs 0.000 description 7
- 229940126214 compound 3 Drugs 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 7
- DMARRXYRWLAEFB-POHAHGRESA-N (5z)-5-(2,3-dihydro-1-benzofuran-5-ylmethylidene)-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound O=C1NC(=S)S\C1=C/C1=CC=C(OCC2)C2=C1 DMARRXYRWLAEFB-POHAHGRESA-N 0.000 description 6
- CSVSEJWBLRTSKN-UHFFFAOYSA-N 5-(dibenzofuran-2-ylmethylidene)-2-imino-1,3-thiazolidin-4-one Chemical compound C1=C(C=CC=2OC3=C(C21)C=CC=C3)C=C3C(N/C(/S3)=N/[H])=O CSVSEJWBLRTSKN-UHFFFAOYSA-N 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- IZGLPKXSQIRIJS-WGLGATGXSA-N C1=C(C=CC=2OC3=C(C21)C=CC=C3)\C=C/3\C(NC(S3)=S)=O.C3=C(C=CC=2OC1=C(C23)C=CC=C1)\C=C/1\C(NC(S1)=S)=O Chemical compound C1=C(C=CC=2OC3=C(C21)C=CC=C3)\C=C/3\C(NC(S3)=S)=O.C3=C(C=CC=2OC1=C(C23)C=CC=C1)\C=C/1\C(NC(S1)=S)=O IZGLPKXSQIRIJS-WGLGATGXSA-N 0.000 description 6
- 101100109871 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aro-8 gene Proteins 0.000 description 6
- IHEQIKISGBQBGO-UHFFFAOYSA-N O1C=CC2=C1C=CC(=C2)C=C2C(N/C(/S2)=N/[H])=O.O2C=CC1=C2C=CC(=C1)C=C1C(N/C(/S1)=N/[H])=O Chemical compound O1C=CC2=C1C=CC(=C2)C=C2C(N/C(/S2)=N/[H])=O.O2C=CC1=C2C=CC(=C1)C=C1C(N/C(/S1)=N/[H])=O IHEQIKISGBQBGO-UHFFFAOYSA-N 0.000 description 6
- PVJVLZLGXKYABM-UHFFFAOYSA-N O1CCC2=C1C=CC(=C2)C=C2C(N/C(/S2)=N/[H])=O.O2CCC1=C2C=CC(=C1)C=C1C(N/C(/S1)=N/[H])=O Chemical compound O1CCC2=C1C=CC(=C2)C=C2C(N/C(/S2)=N/[H])=O.O2CCC1=C2C=CC(=C1)C=C1C(N/C(/S1)=N/[H])=O PVJVLZLGXKYABM-UHFFFAOYSA-N 0.000 description 6
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 6
- 239000012346 acetyl chloride Substances 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- SFJMFSWCBVEHBA-UHFFFAOYSA-M copper(i)-thiophene-2-carboxylate Chemical compound [Cu+].[O-]C(=O)C1=CC=CS1 SFJMFSWCBVEHBA-UHFFFAOYSA-M 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 230000018044 dehydration Effects 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 4
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 4
- JEZSEUPKLJCJRM-UHFFFAOYSA-M 1-ethyl-2-methyl-7,8-dihydrofuro[3,2-e][1,3]benzothiazol-1-ium iodide Chemical compound [I-].C(C)[N+]1=C(SC2=C1C=1CCOC1C=C2)C JEZSEUPKLJCJRM-UHFFFAOYSA-M 0.000 description 4
- AJVNIOHOSGSTBL-UHFFFAOYSA-M 2,4-bis(2-chlorophenyl)-3,3-diethyl-5,5-dimethoxy-2-methyl-4H-1,3-benzothiazol-3-ium trifluoromethanesulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)F.ClC1=C(C=CC=C1)C1C(C=CC2=C1[N+](C(S2)(C)C2=C(C=CC=C2)Cl)(CC)CC)(OC)OC AJVNIOHOSGSTBL-UHFFFAOYSA-M 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 4
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 4
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 4
- BLEKREQWFOZCOW-KELDOBJCSA-N CCN(/C1=C/C(C)=O)C(C=C(C=C2)OC)=C2[S+]/1C(C=C(C)C(C)=C1)=C1Cl.CC(C)=O Chemical compound CCN(/C1=C/C(C)=O)C(C=C(C=C2)OC)=C2[S+]/1C(C=C(C)C(C)=C1)=C1Cl.CC(C)=O BLEKREQWFOZCOW-KELDOBJCSA-N 0.000 description 4
- ZVANKKLECNFZQW-CWIQCBKOSA-N ClC1=C(C=CC=C1)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)O.ClC2=C(C=CC=C2)C2=C(C=CC1=C2N(/C(/S1)=C/C(C)=O)CC)O Chemical compound ClC1=C(C=CC=C1)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)O.ClC2=C(C=CC=C2)C2=C(C=CC1=C2N(/C(/S1)=C/C(C)=O)CC)O ZVANKKLECNFZQW-CWIQCBKOSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 102000009097 Phosphorylases Human genes 0.000 description 4
- 108010073135 Phosphorylases Proteins 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 230000001668 ameliorated effect Effects 0.000 description 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 4
- 229940125773 compound 10 Drugs 0.000 description 4
- 229940125797 compound 12 Drugs 0.000 description 4
- 229940126543 compound 14 Drugs 0.000 description 4
- 229940125758 compound 15 Drugs 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- LCSNDSFWVKMJCT-UHFFFAOYSA-N dicyclohexyl-(2-phenylphenyl)phosphane Chemical compound C1CCCCC1P(C=1C(=CC=CC=1)C=1C=CC=CC=1)C1CCCCC1 LCSNDSFWVKMJCT-UHFFFAOYSA-N 0.000 description 4
- MQRJBSHKWOFOGF-UHFFFAOYSA-L disodium;carbonate;hydrate Chemical compound O.[Na+].[Na+].[O-]C([O-])=O MQRJBSHKWOFOGF-UHFFFAOYSA-L 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000000865 phosphorylative effect Effects 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 229940076133 sodium carbonate monohydrate Drugs 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 4
- 235000019798 tripotassium phosphate Nutrition 0.000 description 4
- HFPZRYXGERMGBS-MFOYZWKCSA-N (1Z)-1-[4-(2,4-dichlorophenyl)-3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene]propan-2-one Chemical compound ClC1=C(C=CC(=C1)Cl)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)OC HFPZRYXGERMGBS-MFOYZWKCSA-N 0.000 description 3
- OWJJXZICZZAVGR-MFOYZWKCSA-N (1Z)-1-[4-(2,5-dichlorophenyl)-3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene]propan-2-one Chemical compound ClC1=C(C=C(C=C1)Cl)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)OC OWJJXZICZZAVGR-MFOYZWKCSA-N 0.000 description 3
- OKFOTJJLEMXLGT-WQRHYEAKSA-N (1Z)-1-[4-(2-chloro-4-methylphenyl)-3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene]propan-2-one Chemical compound ClC1=C(C=CC(=C1)C)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)OC OKFOTJJLEMXLGT-WQRHYEAKSA-N 0.000 description 3
- IDCMBLJKOIUPSL-YVLHZVERSA-N (1Z)-1-[4-(2-chloro-5-methylphenyl)-3-ethyl-5-hydroxy-1,3-benzothiazol-2-ylidene]propan-2-one Chemical compound ClC1=C(C=C(C=C1)C)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)O IDCMBLJKOIUPSL-YVLHZVERSA-N 0.000 description 3
- JZWXMMPTIJLGRP-WQRHYEAKSA-N (1Z)-1-[4-(2-chloro-5-methylphenyl)-3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene]propan-2-one Chemical compound ClC1=C(C=C(C=C1)C)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)OC JZWXMMPTIJLGRP-WQRHYEAKSA-N 0.000 description 3
- QKLXBIHSGMPUQS-FGZHOGPDSA-M (3r,5r)-7-[4-(4-fluorophenyl)-2,5-dimethyl-1-phenylpyrrol-3-yl]-3,5-dihydroxyheptanoate Chemical compound CC1=C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C(C)N1C1=CC=CC=C1 QKLXBIHSGMPUQS-FGZHOGPDSA-M 0.000 description 3
- NUJWKQSEJDYCDB-GNRVTEMESA-N (3s)-1-[(1s,2r,4r)-4-[methyl(propan-2-yl)amino]-2-propylcyclohexyl]-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-2-one Chemical compound CCC[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 NUJWKQSEJDYCDB-GNRVTEMESA-N 0.000 description 3
- VGGUVGVAVAAODK-ZROIWOOFSA-N (5z)-2-amino-5-[(3-cyclopentyloxy-4-methoxyphenyl)methylidene]-1,3-thiazol-4-one Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1\C=C1/SC(=N)NC1=O VGGUVGVAVAAODK-ZROIWOOFSA-N 0.000 description 3
- QRDAPCMJAOQZSU-KQQUZDAGSA-N (e)-3-[4-[(e)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-n-hydroxyprop-2-enamide Chemical compound C1=C(\C=C\C(=O)NO)N(C)C=C1\C=C\C(=O)C1=CC=CC(F)=C1 QRDAPCMJAOQZSU-KQQUZDAGSA-N 0.000 description 3
- APJSHECCIRQQDV-ZRDIBKRKSA-N (e)-3-[4-hydroxy-3-(5,5,8,8-tetramethyl-3-pentoxy-6,7-dihydronaphthalen-2-yl)phenyl]prop-2-enoic acid Chemical compound CCCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1=CC(\C=C\C(O)=O)=CC=C1O APJSHECCIRQQDV-ZRDIBKRKSA-N 0.000 description 3
- DPRJPRMZJGWLHY-HNGSOEQISA-N (e,3r,5s)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)/C=C/C=1C(C(C)C)=NN(C=2N=CC=NC=2)C=1C1=CC=C(F)C=C1 DPRJPRMZJGWLHY-HNGSOEQISA-N 0.000 description 3
- FJZNNKJZHQFMCK-LRDDRELGSA-N 1-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-phenylurea Chemical compound C1(=CC(=CC(=C1[C@H]1[C@@H](C(=O)NC1)NC(=O)NC1=CC=CC=C1)F)OC)F FJZNNKJZHQFMCK-LRDDRELGSA-N 0.000 description 3
- YKYWUHHZZRBGMG-JWTNVVGKSA-N 1-methyl-2-[[(1r,5s)-6-[[5-(trifluoromethyl)pyridin-2-yl]methoxymethyl]-3-azabicyclo[3.1.0]hexan-3-yl]methyl]benzimidazole Chemical compound C1([C@@H]2CN(C[C@@H]21)CC=1N(C2=CC=CC=C2N=1)C)COCC1=CC=C(C(F)(F)F)C=N1 YKYWUHHZZRBGMG-JWTNVVGKSA-N 0.000 description 3
- PSWDQTMAUUQILQ-UHFFFAOYSA-N 2-[(6-methoxy-4-methylquinazolin-2-yl)amino]-5,6-dimethyl-1h-pyrimidin-4-one Chemical compound N1=C(C)C2=CC(OC)=CC=C2N=C1NC1=NC(=O)C(C)=C(C)N1 PSWDQTMAUUQILQ-UHFFFAOYSA-N 0.000 description 3
- CODBZFJPKJDNDT-UHFFFAOYSA-N 2-[[5-[3-(dimethylamino)propyl]-2-methylpyridin-3-yl]amino]-9-(trifluoromethyl)-5,7-dihydropyrimido[5,4-d][1]benzazepine-6-thione Chemical compound CN(C)CCCC1=CN=C(C)C(NC=2N=C3C4=CC=C(C=C4NC(=S)CC3=CN=2)C(F)(F)F)=C1 CODBZFJPKJDNDT-UHFFFAOYSA-N 0.000 description 3
- TXEBWPPWSVMYOA-UHFFFAOYSA-N 4-[3-[(1-amino-2-chloroethyl)amino]propyl]-1-[[3-(2-chlorophenyl)phenyl]methyl]-5-hydroxyimidazolidin-2-one Chemical compound NC(CCl)NCCCC1NC(=O)N(Cc2cccc(c2)-c2ccccc2Cl)C1O TXEBWPPWSVMYOA-UHFFFAOYSA-N 0.000 description 3
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 3
- TZKBVRDEOITLRB-UHFFFAOYSA-N 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2C=C3C=NNC3=NC=2)=C1 TZKBVRDEOITLRB-UHFFFAOYSA-N 0.000 description 3
- KUZSBKJSGSKPJH-VXGBXAGGSA-N 5-[(9R)-6-[(3R)-3-methylmorpholin-4-yl]-11-oxa-1,3,5-triazatricyclo[7.4.0.02,7]trideca-2,4,6-trien-4-yl]pyrazin-2-amine Chemical compound C[C@@H]1COCCN1c1nc(nc2N3CCOC[C@H]3Cc12)-c1cnc(N)cn1 KUZSBKJSGSKPJH-VXGBXAGGSA-N 0.000 description 3
- MITGKKFYIJJQGL-UHFFFAOYSA-N 9-(4-chlorobenzoyl)-6-methylsulfonyl-2,3-dihydro-1H-carbazol-4-one Chemical compound ClC1=CC=C(C(=O)N2C3=CC=C(C=C3C=3C(CCCC2=3)=O)S(=O)(=O)C)C=C1 MITGKKFYIJJQGL-UHFFFAOYSA-N 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- REDUQXCPUSNJOL-UHFFFAOYSA-N C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O Chemical compound C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O REDUQXCPUSNJOL-UHFFFAOYSA-N 0.000 description 3
- NZSQBRZWARZNQH-ZWOACCQCSA-N C1(CC1)NC(=O)O[C@H]1C(C2CC[C@]3([C@@]4(CC[C@@]5(C(C4CCC3[C@]2(CC1)C)[C@@H](CC5)[C@H](C)O)C(=O)O)C)C)(C)C Chemical compound C1(CC1)NC(=O)O[C@H]1C(C2CC[C@]3([C@@]4(CC[C@@]5(C(C4CCC3[C@]2(CC1)C)[C@@H](CC5)[C@H](C)O)C(=O)O)C)C)(C)C NZSQBRZWARZNQH-ZWOACCQCSA-N 0.000 description 3
- QCMHGCDOZLWPOT-FMNCTDSISA-N COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 Chemical compound COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 QCMHGCDOZLWPOT-FMNCTDSISA-N 0.000 description 3
- CYSWUSAYJNCAKA-FYJFLYSWSA-N ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O Chemical compound ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O CYSWUSAYJNCAKA-FYJFLYSWSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000020358 Learning disease Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000026139 Memory disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- OGSVZPRWAGBSLA-UHFFFAOYSA-N N-(5-bromo-2,3-dihydro-1-benzofuran-4-yl)ethanethioamide Chemical compound BrC=1C=CC2=C(CCO2)C1NC(C)=S OGSVZPRWAGBSLA-UHFFFAOYSA-N 0.000 description 3
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
- KSQVGVMZECCPAT-AEFFLSMTSA-N [(1R)-4-phenyl-1-[[(2R)-2-(pyrazine-2-carbonylamino)pentanoyl]amino]butyl]boronic acid Chemical compound B([C@H](CCCC1=CC=CC=C1)NC(=O)[C@@H](CCC)NC(=O)C2=NC=CN=C2)(O)O KSQVGVMZECCPAT-AEFFLSMTSA-N 0.000 description 3
- NELWQUQCCZMRPB-UBPLGANQSA-N [(2r,3r,4r,5r)-4-acetyloxy-5-(4-amino-5-ethenyl-2-oxopyrimidin-1-yl)-2-methyloxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](C)O[C@H]1N1C(=O)N=C(N)C(C=C)=C1 NELWQUQCCZMRPB-UBPLGANQSA-N 0.000 description 3
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- KSCRVOKQPYZBHZ-IXPOFIJOSA-N benzyl n-[(2s)-1-[[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@H]1C(NCC1)=O)C(=O)C=1SC2=CC=CC=C2N=1)C(C)C)C(=O)OCC1=CC=CC=C1 KSCRVOKQPYZBHZ-IXPOFIJOSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 3
- 230000009702 cancer cell proliferation Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- AEULIVPVIDOLIN-UHFFFAOYSA-N cep-11981 Chemical compound C1=C2C3=C4CNC(=O)C4=C4C5=CN(C)N=C5CCC4=C3N(CC(C)C)C2=CC=C1NC1=NC=CC=N1 AEULIVPVIDOLIN-UHFFFAOYSA-N 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 229940127206 compound 14d Drugs 0.000 description 3
- 229940125796 compound 3d Drugs 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- OVJMIWIVPWPZMN-UHFFFAOYSA-N dibenzofuran-2-carbaldehyde Chemical compound C1=CC=C2C3=CC(C=O)=CC=C3OC2=C1 OVJMIWIVPWPZMN-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 201000003723 learning disability Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- DAFHCFQPQMYDFI-UHFFFAOYSA-N n-(3-methoxyphenyl)-2,2-dimethylpropanamide Chemical compound COC1=CC=CC(NC(=O)C(C)(C)C)=C1 DAFHCFQPQMYDFI-UHFFFAOYSA-N 0.000 description 3
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 3
- MUJNAWXXOJRNGK-UHFFFAOYSA-N n-[3-(6-methyl-1,2,3,4-tetrahydrocarbazol-9-yl)propyl]cyclohexanamine Chemical compound C1=2CCCCC=2C2=CC(C)=CC=C2N1CCCNC1CCCCC1 MUJNAWXXOJRNGK-UHFFFAOYSA-N 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
- KIWUVOGUEXMXSV-UHFFFAOYSA-N rhodanine Chemical compound O=C1CSC(=S)N1 KIWUVOGUEXMXSV-UHFFFAOYSA-N 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 3
- FRACPXUHUTXLCX-BELIEFIBSA-N tert-butyl N-{1-[(1S)-1-{[(1R,2S)-1-(benzylcarbamoyl)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}-2-cyclopropylethyl]-2-oxopyridin-3-yl}carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CN(C1=O)[C@@H](CC2CC2)C(=O)N[C@@H](C[C@@H]3CCNC3=O)[C@H](C(=O)NCC4=CC=CC=C4)O FRACPXUHUTXLCX-BELIEFIBSA-N 0.000 description 3
- 210000001631 vena cava inferior Anatomy 0.000 description 3
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 3
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 2
- NHDNXYLLAQDNEW-PXNMLYILSA-N (1z)-1-(9-chloro-1-ethyl-[1]benzofuro[3,2-e][1,3]benzothiazol-2-ylidene)propan-2-one Chemical compound C1=C(Cl)C=C2C3=C4N(CC)\C(=C\C(C)=O)SC4=CC=C3OC2=C1 NHDNXYLLAQDNEW-PXNMLYILSA-N 0.000 description 2
- MNKCGUKVRJZKEQ-MIXQCLKLSA-N (1z,5z)-cycloocta-1,5-diene;iridium;methanol Chemical compound [Ir].[Ir].OC.OC.C\1C\C=C/CC\C=C/1.C\1C\C=C/CC\C=C/1 MNKCGUKVRJZKEQ-MIXQCLKLSA-N 0.000 description 2
- WLWNRAWQDZRXMB-YLFCFFPRSA-N (2r,3r,4r,5s)-n,3,4,5-tetrahydroxy-1-(4-phenoxyphenyl)sulfonylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 WLWNRAWQDZRXMB-YLFCFFPRSA-N 0.000 description 2
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 2
- VPMIAOSOTOODMY-KJAPKAAFSA-N (4r)-6-[(e)-2-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1/C=C/C=1C(C(C)C)=NC(C(C)(C)C)=CC=1C1=CC=C(F)C=C1 VPMIAOSOTOODMY-KJAPKAAFSA-N 0.000 description 2
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 2
- VAVHMEQFYYBAPR-ITWZMISCSA-N (e,3r,5s)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(C=2C=CC(F)=CC=2)=CN1C1=CC=CC=C1 VAVHMEQFYYBAPR-ITWZMISCSA-N 0.000 description 2
- CJHUKYBAIZQYQU-UHFFFAOYSA-N 1-(2-amino-5-bromo-1-benzofuran-4-yl)ethanethione Chemical compound C(C)(=S)C1=C(C=CC2=C1C=C(O2)N)Br CJHUKYBAIZQYQU-UHFFFAOYSA-N 0.000 description 2
- LLLBDLDNTMMZHL-UHFFFAOYSA-N 1-benzofuran-5-carbaldehyde Chemical compound O=CC1=CC=C2OC=CC2=C1 LLLBDLDNTMMZHL-UHFFFAOYSA-N 0.000 description 2
- RWPLKRGISDOAAG-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-4-amine Chemical compound NC1=CC=CC2=C1CCO2 RWPLKRGISDOAAG-UHFFFAOYSA-N 0.000 description 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 2
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 2
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 2
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 2
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 2
- KPBISARAIMKQTI-UHFFFAOYSA-M 4-(2-chloro-4-methylphenyl)-3-ethyl-5-methoxy-2-methyl-1,3-benzothiazol-3-ium trifluoromethanesulfonate Chemical compound S(=O)(=O)(C(F)(F)F)[O-].ClC1=C(C=CC(=C1)C)C1=C(C=CC2=C1[N+](=C(S2)C)CC)OC KPBISARAIMKQTI-UHFFFAOYSA-M 0.000 description 2
- MZFFKEUUXXCGBH-UHFFFAOYSA-M 4-(2-chloro-5-methylphenyl)-3-ethyl-5-methoxy-2-methyl-1,3-benzothiazol-3-ium trifluoromethanesulfonate Chemical compound S(=O)(=O)(C(F)(F)F)[O-].ClC1=C(C=C(C=C1)C)C1=C(C=CC2=C1[N+](=C(S2)C)CC)OC MZFFKEUUXXCGBH-UHFFFAOYSA-M 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 2
- TXNLQUKVUJITMX-UHFFFAOYSA-N 4-tert-butyl-2-(4-tert-butylpyridin-2-yl)pyridine Chemical compound CC(C)(C)C1=CC=NC(C=2N=CC=C(C=2)C(C)(C)C)=C1 TXNLQUKVUJITMX-UHFFFAOYSA-N 0.000 description 2
- NDSRLVCYAXEUAV-UHFFFAOYSA-N 5-bromo-1-benzofuran-4-amine Chemical compound NC1=C(Br)C=CC2=C1C=CO2 NDSRLVCYAXEUAV-UHFFFAOYSA-N 0.000 description 2
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- QACJLKJYGMFABD-UHFFFAOYSA-N N-(5-bromo-1-benzofuran-4-yl)acetamide Chemical compound N(C(=O)C)C1=C(C=CC2=C1C=CO2)Br QACJLKJYGMFABD-UHFFFAOYSA-N 0.000 description 2
- JPSFOMMMVDBCQX-UHFFFAOYSA-N N-(5-bromo-2,3-dihydro-1-benzofuran-4-yl)acetamide Chemical compound C(C)(=O)NC1=C(C=CC2=C1CCO2)Br JPSFOMMMVDBCQX-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 2
- JFOZKMSJYSPYLN-QHCPKHFHSA-N lifitegrast Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C=2C(=C3CCN(CC3=CC=2Cl)C(=O)C=2C=C3OC=CC3=CC=2)Cl)C(O)=O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- XZXATLHJLNWKRC-UHFFFAOYSA-N n-(2,3-dihydro-1-benzofuran-4-yl)acetamide Chemical compound CC(=O)NC1=CC=CC2=C1CCO2 XZXATLHJLNWKRC-UHFFFAOYSA-N 0.000 description 2
- VLQCFCOZILVCKP-UHFFFAOYSA-N n-[2-(2-hydroxyethyl)-3-methoxyphenyl]-2,2-dimethylpropanamide Chemical compound COC1=CC=CC(NC(=O)C(C)(C)C)=C1CCO VLQCFCOZILVCKP-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- YGSFNCRAZOCNDJ-UHFFFAOYSA-N propan-2-one Chemical compound CC(C)=O.CC(C)=O YGSFNCRAZOCNDJ-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- KXUUVZJKTZWVAH-PXNMLYILSA-N (1Z)-1-[4-(2,4-dichlorophenyl)-3-ethyl-5-hydroxy-1,3-benzothiazol-2-ylidene]propan-2-one Chemical compound ClC1=C(C=CC(=C1)Cl)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)O KXUUVZJKTZWVAH-PXNMLYILSA-N 0.000 description 1
- DKNCZYCNTZOZCA-PXNMLYILSA-N (1Z)-1-[4-(2,5-dichlorophenyl)-3-ethyl-5-hydroxy-1,3-benzothiazol-2-ylidene]propan-2-one Chemical compound ClC1=C(C=C(C=C1)Cl)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)O DKNCZYCNTZOZCA-PXNMLYILSA-N 0.000 description 1
- XFGZCMCCVNWJKI-YVLHZVERSA-N (1Z)-1-[4-(2-chloro-4-methylphenyl)-3-ethyl-5-hydroxy-1,3-benzothiazol-2-ylidene]propan-2-one Chemical compound ClC1=C(C=CC(=C1)C)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)O XFGZCMCCVNWJKI-YVLHZVERSA-N 0.000 description 1
- WMHIOOQUIGWQAU-YBEGLDIGSA-N (1Z)-1-[4-(2-chlorophenyl)-3-ethyl-5-hydroxy-1,3-benzothiazol-2-ylidene]propan-2-one Chemical compound ClC1=C(C=CC=C1)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)O WMHIOOQUIGWQAU-YBEGLDIGSA-N 0.000 description 1
- BWVBHEXJDRPALC-BOPFTXTBSA-N (1Z)-1-[4-(2-chlorophenyl)-3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene]propan-2-one Chemical compound ClC1=C(C=CC=C1)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)OC BWVBHEXJDRPALC-BOPFTXTBSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- IZNKZNXIXHLRGY-JYRVWZFOSA-N (1z)-1-(1-ethyl-7,8-dihydrofuro[3,2-e][1,3]benzothiazol-2-ylidene)propan-2-one Chemical compound C1=C2OCCC2=C2N(CC)\C(=C\C(C)=O)SC2=C1 IZNKZNXIXHLRGY-JYRVWZFOSA-N 0.000 description 1
- WJCUXFRHZYIEOR-YVLHZVERSA-N (1z)-1-(1-ethyl-8-methyl-[1]benzofuro[3,2-e][1,3]benzothiazol-2-ylidene)propan-2-one Chemical compound CC1=CC=C2C3=C4N(CC)\C(=C\C(C)=O)SC4=CC=C3OC2=C1 WJCUXFRHZYIEOR-YVLHZVERSA-N 0.000 description 1
- KAOGHERYRZIKQY-YVLHZVERSA-N (1z)-1-(1-ethyl-9-methyl-[1]benzofuro[3,2-e][1,3]benzothiazol-2-ylidene)propan-2-one Chemical compound C1=C(C)C=C2C3=C4N(CC)\C(=C\C(C)=O)SC4=CC=C3OC2=C1 KAOGHERYRZIKQY-YVLHZVERSA-N 0.000 description 1
- QIAFGVQZUDBBOX-YBEGLDIGSA-N (1z)-1-(1-ethyl-[1]benzofuro[3,2-e][1,3]benzothiazol-2-ylidene)propan-2-one Chemical compound C1=CC=C2C3=C4N(CC)\C(=C\C(C)=O)SC4=CC=C3OC2=C1 QIAFGVQZUDBBOX-YBEGLDIGSA-N 0.000 description 1
- RUQRAQTVHSATEP-PXNMLYILSA-N (1z)-1-(8-chloro-1-ethyl-[1]benzofuro[3,2-e][1,3]benzothiazol-2-ylidene)propan-2-one Chemical compound ClC1=CC=C2C3=C4N(CC)\C(=C\C(C)=O)SC4=CC=C3OC2=C1 RUQRAQTVHSATEP-PXNMLYILSA-N 0.000 description 1
- OSRJVVHTIPDBRH-UHFFFAOYSA-N (2,4-dichlorophenyl)boronic acid Chemical compound ClC1=C(C=CC(=C1)Cl)B(O)O.ClC1=C(C=CC(=C1)Cl)B(O)O OSRJVVHTIPDBRH-UHFFFAOYSA-N 0.000 description 1
- NNTFPBXQPOQRBT-UHFFFAOYSA-N (2,5-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=CC=C1Cl NNTFPBXQPOQRBT-UHFFFAOYSA-N 0.000 description 1
- UKYCKUPXBPLXBA-UHFFFAOYSA-N (2-chloro-4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C(Cl)=C1 UKYCKUPXBPLXBA-UHFFFAOYSA-N 0.000 description 1
- JMUXNVYJDBCLPF-UHFFFAOYSA-N (2-chloro-5-methylphenyl)boronic acid Chemical compound CC1=CC=C(Cl)C(B(O)O)=C1 JMUXNVYJDBCLPF-UHFFFAOYSA-N 0.000 description 1
- RRCMGJCFMJBHQC-UHFFFAOYSA-N (2-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Cl RRCMGJCFMJBHQC-UHFFFAOYSA-N 0.000 description 1
- GNQYZNONZWNPAL-POHAHGRESA-N (5z)-5-(1-benzofuran-5-ylmethylidene)-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound O=C1NC(=S)S\C1=C/C1=CC=C(OC=C2)C2=C1 GNQYZNONZWNPAL-POHAHGRESA-N 0.000 description 1
- GDCHIXYTIMPISQ-ZSOIEALJSA-N (5z)-5-(dibenzofuran-2-ylmethylidene)-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound O=C1NC(=S)S\C1=C/C1=CC=C(OC=2C3=CC=CC=2)C3=C1 GDCHIXYTIMPISQ-ZSOIEALJSA-N 0.000 description 1
- FZTLLUYFWAOGGB-UHFFFAOYSA-N 1,4-dioxane dioxane Chemical compound C1COCCO1.C1COCCO1 FZTLLUYFWAOGGB-UHFFFAOYSA-N 0.000 description 1
- LBQBGPSBBYURIZ-UHFFFAOYSA-N 1-(2-amino-3-bromo-6-methoxyphenyl)-2-chloroethanone Chemical compound NC1=C(C(=CC=C1Br)OC)C(CCl)=O LBQBGPSBBYURIZ-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
- XMOWGNRHWXGYJL-UHFFFAOYSA-N 2-(2-chloro-4,5-dimethylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound ClC1=C(C=C(C(=C1)C)C)B1OC(C(O1)(C)C)(C)C XMOWGNRHWXGYJL-UHFFFAOYSA-N 0.000 description 1
- GRHRWVRWLAIBGN-UHFFFAOYSA-N 2-amino-5-(2,3-dihydro-1-benzofuran-5-ylmethylidene)-1,3-thiazol-4-one Chemical compound S1C(N)=NC(=O)C1=CC1=CC=C(OCC2)C2=C1 GRHRWVRWLAIBGN-UHFFFAOYSA-N 0.000 description 1
- PRQDMSJEMCRFMI-UHFFFAOYSA-N 2-bromo-5-methoxyaniline Chemical compound COC1=CC=C(Br)C(N)=C1 PRQDMSJEMCRFMI-UHFFFAOYSA-N 0.000 description 1
- XXDYTRMDTWMXBY-UHFFFAOYSA-N 2-methyl-7,8-dihydrofuro[3,2-e][1,3]benzothiazole Chemical compound CC=1SC2=C(N1)C=1CCOC1C=C2 XXDYTRMDTWMXBY-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- UGWULZWUXSCWPX-UHFFFAOYSA-N 2-sulfanylideneimidazolidin-4-one Chemical compound O=C1CNC(=S)N1 UGWULZWUXSCWPX-UHFFFAOYSA-N 0.000 description 1
- QWAJMQNJBCMMRG-UHFFFAOYSA-M 4-(2-chloro-4,5-dimethylphenyl)-3-ethyl-5-methoxy-2-methyl-1,3-benzothiazol-3-ium trifluoromethanesulfonate Chemical compound S(=O)(=O)(C(F)(F)F)[O-].ClC1=C(C=C(C(=C1)C)C)C1=C(C=CC2=C1[N+](=C(S2)C)CC)OC QWAJMQNJBCMMRG-UHFFFAOYSA-M 0.000 description 1
- HFXMVWFRGIUXDY-UHFFFAOYSA-N 4-(2-chloro-4,5-dimethylphenyl)-5-methoxy-2-methyl-1,3-benzothiazole Chemical compound ClC1=C(C=C(C(=C1)C)C)C1=C(C=CC2=C1N=C(S2)C)OC HFXMVWFRGIUXDY-UHFFFAOYSA-N 0.000 description 1
- RDHJYNFDKQDPFV-UHFFFAOYSA-N 4-(2-chloro-4-methylphenyl)-5-methoxy-2-methyl-1,3-benzothiazole Chemical compound ClC1=C(C=CC(=C1)C)C1=C(C=CC2=C1N=C(S2)C)OC RDHJYNFDKQDPFV-UHFFFAOYSA-N 0.000 description 1
- DIVJEHITLGYZLE-UHFFFAOYSA-N 4-(2-chlorophenyl)-5-methoxy-2-methyl-1,3-benzothiazole Chemical compound ClC1=C(C=CC=C1)C1=C(C=CC2=C1N=C(S2)C)OC DIVJEHITLGYZLE-UHFFFAOYSA-N 0.000 description 1
- NKFWYTJQWGMGTN-UHFFFAOYSA-N 4-amino-5-bromo-1-benzofuran-3-one Chemical compound NC1=C(C=CC2=C1C(CO2)=O)Br NKFWYTJQWGMGTN-UHFFFAOYSA-N 0.000 description 1
- XZDLYAMELHTIIL-UHFFFAOYSA-N 4-amino-5-bromo-2,3-dihydro-1-benzofuran-3-ol Chemical compound NC1=C(C=CC2=C1C(CO2)O)Br XZDLYAMELHTIIL-UHFFFAOYSA-N 0.000 description 1
- DTORLTOHGPCUAI-UHFFFAOYSA-N 4-bromo-5-methoxy-2-methyl-1,3-benzothiazole Chemical compound BrC1=C(C=CC2=C1N=C(S2)C)OC DTORLTOHGPCUAI-UHFFFAOYSA-N 0.000 description 1
- HNQLMBJUMVLFCF-UHFFFAOYSA-N 4-chloro-1,2-dimethylbenzene Chemical compound CC1=CC=C(Cl)C=C1C HNQLMBJUMVLFCF-UHFFFAOYSA-N 0.000 description 1
- ABQFPEZFBNGHOM-UHFFFAOYSA-N 5-(1-benzofuran-5-ylmethylidene)-2-imino-1,3-thiazolidin-4-one Chemical compound O1C=CC2=C1C=CC(=C2)C=C2C(N/C(/S2)=N/[H])=O ABQFPEZFBNGHOM-UHFFFAOYSA-N 0.000 description 1
- SAQMNBWVOKYKPZ-UHFFFAOYSA-N 5-methoxy-2-methyl-1,3-benzothiazole Chemical compound COC1=CC=C2SC(C)=NC2=C1 SAQMNBWVOKYKPZ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- YHGZTTFKQDQCTD-UHFFFAOYSA-N BrC1=C(C=CC2=C1N=C(S2)C)OC.BrC2=C(C=CC1=C2N=C(S1)C)OC Chemical compound BrC1=C(C=CC2=C1N=C(S2)C)OC.BrC2=C(C=CC1=C2N=C(S1)C)OC YHGZTTFKQDQCTD-UHFFFAOYSA-N 0.000 description 1
- YTHXZCCUJGGLCE-UHFFFAOYSA-N C(C)(=O)NC1=C(C=CC2=C1CCO2)C(C)=O Chemical compound C(C)(=O)NC1=C(C=CC2=C1CCO2)C(C)=O YTHXZCCUJGGLCE-UHFFFAOYSA-N 0.000 description 1
- MTBGHQTWDLTYMD-UHFFFAOYSA-N C(C)(=O)NC1=CC=CC2=C1CCO2.C(C)(=O)NC2=CC=CC1=C2CCO1 Chemical compound C(C)(=O)NC1=CC=CC2=C1CCO2.C(C)(=O)NC2=CC=CC1=C2CCO1 MTBGHQTWDLTYMD-UHFFFAOYSA-N 0.000 description 1
- MCTOMZPGOFTZTH-HVYJKNPQSA-N C(C)N1/C(/SC2=C1C=1C3=C(OC1C=C2)C=C(C=C3)C)=C/C(C)=O.C(C)N3/C(/SC2=C3C=3C1=C(OC3C=C2)C=C(C=C1)C)=C/C(C)=O Chemical compound C(C)N1/C(/SC2=C1C=1C3=C(OC1C=C2)C=C(C=C3)C)=C/C(C)=O.C(C)N3/C(/SC2=C3C=3C1=C(OC3C=C2)C=C(C=C1)C)=C/C(C)=O MCTOMZPGOFTZTH-HVYJKNPQSA-N 0.000 description 1
- ZXQPIOVSMYYQRO-HVHKRRFMSA-N C(C)N1/C(/SC2=C1C=1C3=C(OC1C=C2)C=CC(=C3)C)=C/C(C)=O.CC(C)=O Chemical compound C(C)N1/C(/SC2=C1C=1C3=C(OC1C=C2)C=CC(=C3)C)=C/C(C)=O.CC(C)=O ZXQPIOVSMYYQRO-HVHKRRFMSA-N 0.000 description 1
- XPHFLCRQOZQPCP-CWIQCBKOSA-N C(C)N1/C(/SC2=C1C=1C3=C(OC1C=C2)C=CC=C3)=C/C(C)=O.C(C)N3/C(/SC2=C3C=3C1=C(OC3C=C2)C=CC=C1)=C/C(C)=O Chemical compound C(C)N1/C(/SC2=C1C=1C3=C(OC1C=C2)C=CC=C3)=C/C(C)=O.C(C)N3/C(/SC2=C3C=3C1=C(OC3C=C2)C=CC=C1)=C/C(C)=O XPHFLCRQOZQPCP-CWIQCBKOSA-N 0.000 description 1
- PPAKAGNSCNBDRJ-BJLOMCMNSA-N C(C)N1/C(/SC2=C1C=1CCOC1C=C2)=C/C(C)=O.C(C)N2/C(/SC1=C2C=2CCOC2C=C1)=C/C(C)=O Chemical compound C(C)N1/C(/SC2=C1C=1CCOC1C=C2)=C/C(C)=O.C(C)N2/C(/SC1=C2C=2CCOC2C=C1)=C/C(C)=O PPAKAGNSCNBDRJ-BJLOMCMNSA-N 0.000 description 1
- PLWVBRPMTVTMGZ-JSNLGJQVSA-N C1=C(C=CC=2OC3=C(C21)C=CC=C3)\C=C/3\C(NC(N3)=S)=O.C3=C(C=CC=2OC1=C(C23)C=CC=C1)\C=C/1\C(NC(N1)=S)=O Chemical compound C1=C(C=CC=2OC3=C(C21)C=CC=C3)\C=C/3\C(NC(N3)=S)=O.C3=C(C=CC=2OC1=C(C23)C=CC=C1)\C=C/1\C(NC(N1)=S)=O PLWVBRPMTVTMGZ-JSNLGJQVSA-N 0.000 description 1
- MEVIRXLYTDDQMR-XABTVYMYSA-N CC=1C(=CC2=C(OC3=C2C=2N(/C(/SC2C=C3)=C/C(C)=O)CC)C1)C.ClC1=CC3=C(OC2=C3C=3N(/C(/SC3C=C2)=C/C(C)=O)CC)C=C1 Chemical compound CC=1C(=CC2=C(OC3=C2C=2N(/C(/SC2C=C3)=C/C(C)=O)CC)C1)C.ClC1=CC3=C(OC2=C3C=3N(/C(/SC3C=C2)=C/C(C)=O)CC)C=C1 MEVIRXLYTDDQMR-XABTVYMYSA-N 0.000 description 1
- BYPHOBCFQBLUOE-UHFFFAOYSA-N CC=1SC2=C(N1)C=1CCOC1C=C2.CC=2SC1=C(N2)C=2CCOC2C=C1 Chemical compound CC=1SC2=C(N1)C=1CCOC1C=C2.CC=2SC1=C(N2)C=2CCOC2C=C1 BYPHOBCFQBLUOE-UHFFFAOYSA-N 0.000 description 1
- WMWGBKPDXPZSPU-NVMQZCJTSA-O CCN(/C1=C/C(C)=O)C(C=C(C=C2)O)=C2[S+]/1C(C=C(C)C(C)=C1)=C1Cl.CC(C)=O Chemical compound CCN(/C1=C/C(C)=O)C(C=C(C=C2)O)=C2[S+]/1C(C=C(C)C(C)=C1)=C1Cl.CC(C)=O WMWGBKPDXPZSPU-NVMQZCJTSA-O 0.000 description 1
- 101100328957 Caenorhabditis elegans clk-1 gene Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PFSJTCSJFOXHBT-UHFFFAOYSA-N ClC1(SC2=C(N1)C(=C(C=C2)OC)C2=C(C=CC(=C2)C)Cl)C Chemical compound ClC1(SC2=C(N1)C(=C(C=C2)OC)C2=C(C=CC(=C2)C)Cl)C PFSJTCSJFOXHBT-UHFFFAOYSA-N 0.000 description 1
- BKQCUTMKUVPOTI-UHFFFAOYSA-N ClC1=C(C=C(C(=C1)C)C)B1OC(C(O1)(C)C)(C)C.ClC1=C(C=C(C(=C1)C)C)B1OC(C(O1)(C)C)(C)C Chemical compound ClC1=C(C=C(C(=C1)C)C)B1OC(C(O1)(C)C)(C)C.ClC1=C(C=C(C(=C1)C)C)B1OC(C(O1)(C)C)(C)C BKQCUTMKUVPOTI-UHFFFAOYSA-N 0.000 description 1
- TXVNXHWMZCCWJC-UHFFFAOYSA-N ClC1=C(C=C(C(=C1)C)C)C1=C(C=CC2=C1N=C(S2)C)OC.ClC2=C(C=C(C(=C2)C)C)C2=C(C=CC1=C2N=C(S1)C)OC Chemical compound ClC1=C(C=C(C(=C1)C)C)C1=C(C=CC2=C1N=C(S2)C)OC.ClC2=C(C=C(C(=C2)C)C)C2=C(C=CC1=C2N=C(S1)C)OC TXVNXHWMZCCWJC-UHFFFAOYSA-N 0.000 description 1
- DPLYQDKSVZYXHH-BODMRAEUSA-N ClC1=C(C=C(C=C1)Cl)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)O.ClC2=C(C=C(C=C2)Cl)C2=C(C=CC1=C2N(/C(/S1)=C/C(C)=O)CC)O Chemical compound ClC1=C(C=C(C=C1)Cl)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)O.ClC2=C(C=C(C=C2)Cl)C2=C(C=CC1=C2N(/C(/S1)=C/C(C)=O)CC)O DPLYQDKSVZYXHH-BODMRAEUSA-N 0.000 description 1
- YTONZILPEDEQDV-HVHKRRFMSA-N ClC1=C(C=CC(=C1)C)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)O.CC(C)=O Chemical compound ClC1=C(C=CC(=C1)C)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)O.CC(C)=O YTONZILPEDEQDV-HVHKRRFMSA-N 0.000 description 1
- PTFMZFUJSZTAHS-BODMRAEUSA-N ClC1=C(C=CC(=C1)Cl)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)O.ClC2=C(C=CC(=C2)Cl)C2=C(C=CC1=C2N(/C(/S1)=C/C(C)=O)CC)O Chemical compound ClC1=C(C=CC(=C1)Cl)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)O.ClC2=C(C=CC(=C2)Cl)C2=C(C=CC1=C2N(/C(/S1)=C/C(C)=O)CC)O PTFMZFUJSZTAHS-BODMRAEUSA-N 0.000 description 1
- KKSBINIJQAUSKK-CRJJHAOZSA-N ClC1=C(C=CC=C1)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)OC.ClC2=C(C=CC=C2)C2=C(C=CC1=C2N(/C(/S1)=C/C(C)=O)CC)OC Chemical compound ClC1=C(C=CC=C1)C1=C(C=CC2=C1N(/C(/S2)=C/C(C)=O)CC)OC.ClC2=C(C=CC=C2)C2=C(C=CC1=C2N(/C(/S1)=C/C(C)=O)CC)OC KKSBINIJQAUSKK-CRJJHAOZSA-N 0.000 description 1
- QSNXHPIIRAOVNG-UHFFFAOYSA-N ClC1=C(C=CC=C1)C1=C(C=CC2=C1N=C(S2)C)OC.CC=2SC1=C(N2)C=CC=C1 Chemical compound ClC1=C(C=CC=C1)C1=C(C=CC2=C1N=C(S2)C)OC.CC=2SC1=C(N2)C=CC=C1 QSNXHPIIRAOVNG-UHFFFAOYSA-N 0.000 description 1
- HBFZQCVWMJVABR-BODMRAEUSA-N ClC=1C=CC2=C(OC3=C2C=2N(/C(/SC2C=C3)=C/C(C)=O)CC)C1.ClC=1C=CC3=C(OC2=C3C=3N(/C(/SC3C=C2)=C/C(C)=O)CC)C1 Chemical compound ClC=1C=CC2=C(OC3=C2C=2N(/C(/SC2C=C3)=C/C(C)=O)CC)C1.ClC=1C=CC3=C(OC2=C3C=3N(/C(/SC3C=C2)=C/C(C)=O)CC)C1 HBFZQCVWMJVABR-BODMRAEUSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- ZRKXSGQYUPXDBW-UHFFFAOYSA-N NC1=C(C(=CC=C1Br)OC)C(CCl)=O.NC1=C(C(=CC=C1Br)OC)C(CCl)=O Chemical compound NC1=C(C(=CC=C1Br)OC)C(CCl)=O.NC1=C(C(=CC=C1Br)OC)C(CCl)=O ZRKXSGQYUPXDBW-UHFFFAOYSA-N 0.000 description 1
- QCEZJGIOTRNBGC-UHFFFAOYSA-N NC1=C(C=CC2=C1C(CO2)=O)Br.NC2=C(C=CC1=C2C(CO1)=O)Br Chemical compound NC1=C(C=CC2=C1C(CO2)=O)Br.NC2=C(C=CC1=C2C(CO1)=O)Br QCEZJGIOTRNBGC-UHFFFAOYSA-N 0.000 description 1
- ANMORJJRWGKQOI-UHFFFAOYSA-N NC1=C(C=CC2=C1C(CO2)O)Br.NC2=C(C=CC1=C2C(CO1)O)Br Chemical compound NC1=C(C=CC2=C1C(CO2)O)Br.NC2=C(C=CC1=C2C(CO1)O)Br ANMORJJRWGKQOI-UHFFFAOYSA-N 0.000 description 1
- LGMIQUYMHSOOSW-UHFFFAOYSA-N NC1=CC=CC2=C1CCO2.NC2=CC=CC1=C2CCO1 Chemical compound NC1=CC=CC2=C1CCO2.NC2=CC=CC1=C2CCO1 LGMIQUYMHSOOSW-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- AOUNRHNLDRQKHR-VRGQSPJESA-N O1C=CC2=C1C=CC(=C2)\C=C/2\C(NC(S2)=S)=O.O2C=CC1=C2C=CC(=C1)\C=C/1\C(NC(S1)=S)=O Chemical compound O1C=CC2=C1C=CC(=C2)\C=C/2\C(NC(S2)=S)=O.O2C=CC1=C2C=CC(=C1)\C=C/1\C(NC(S1)=S)=O AOUNRHNLDRQKHR-VRGQSPJESA-N 0.000 description 1
- HYWIXBRHXXIFGE-VRGQSPJESA-N O1CCC2=C1C=CC(=C2)\C=C/2\C(NC(S2)=S)=O.O2CCC1=C2C=CC(=C1)\C=C/1\C(NC(S1)=S)=O Chemical compound O1CCC2=C1C=CC(=C2)\C=C/2\C(NC(S2)=S)=O.O2CCC1=C2C=CC(=C1)\C=C/1\C(NC(S1)=S)=O HYWIXBRHXXIFGE-VRGQSPJESA-N 0.000 description 1
- WVEOGXHSWOXCMQ-UHFFFAOYSA-N OCCC1=C(C=CC=C1OC)NC(C(C)(C)C)=O.C(C(C)(C)C)(=O)NC1=C(C(=CC=C1)OC)CCO Chemical compound OCCC1=C(C=CC=C1OC)NC(C(C)(C)C)=O.C(C(C)(C)C)(=O)NC1=C(C(=CC=C1)OC)CCO WVEOGXHSWOXCMQ-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- YIQXKMNBAKPOFE-UHFFFAOYSA-M [I-].[S+]1=CNC=C1 Chemical compound [I-].[S+]1=CNC=C1 YIQXKMNBAKPOFE-UHFFFAOYSA-M 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 150000004292 cyclic ethers Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- ZYCMDWDFIQDPLP-UHFFFAOYSA-N hbr bromine Chemical compound Br.Br ZYCMDWDFIQDPLP-UHFFFAOYSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- ABPVOVVFNFRBRZ-UHFFFAOYSA-N n-bromo-3-methoxyaniline Chemical compound COC1=CC=CC(NBr)=C1 ABPVOVVFNFRBRZ-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- RMNIZOOYFMNEJJ-UHFFFAOYSA-K tripotassium;phosphate;hydrate Chemical compound O.[K+].[K+].[K+].[O-]P([O-])([O-])=O RMNIZOOYFMNEJJ-UHFFFAOYSA-K 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
本開示は、一又は複数の実施形態において、下記一般式(I)で表される化合物若しくはそのプロドラッグ又はその製薬上許容される塩に関する。
一般式(I)又は(III)で表される化合物若しくはそのプロドラッグ又はその製薬上許容される塩が精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療に効果を示す。そのメカニズムは以下のように推定される。すなわち、一般式(I)又は(III)で表される化合物又はその製薬上許容される塩は、タウ(tau)蛋白質の異常リン酸化を抑制でき、加えてアミロイド前駆体蛋白質(APP)のリン酸化を抑制することによりアミロイドベータ(Ab)ペプチドの産生を抑制でき、それにより、精神神経疾患の予防、改善、進行抑制、及び/又は、治療しうると推定される。さらに、そのリン酸化酵素活性阻害効果により悪性腫瘍を予防、改善、進行抑制、及び/又は、治療しうると推定される。但し、本開示はこの推定に限定して解釈されなくてもよい。また、一般式(I)又は(III)で表される化合物若しくはそのプロドラッグ又はその製薬上許容される塩は、一又は複数の実施形態において、脳内移行性及び経口吸収性を発揮する。それにより、より効果的に精神神経疾患又は悪性腫瘍を予防、改善、進行抑制、及び/又は、治療しうる。
[A1] 下記一般式(I)で表される化合物若しくはそのプロドラッグ又はその製薬上許容される塩;
[A2]
[A3]
下記一般式(III)で表される化合物若しくはそのプロドラッグ又はその製薬上許容される塩;
[A4]
[A5] [A1]から[A4]のいずれかに記載の化合物若しくはそのプロドラッグ又はその製薬上許容される塩を有効成分として含有する医薬組成物;
[A6] 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療のための医薬組成物であって、[A1]から[A4]のいずれかに記載の化合物若しくはそのプロドラッグ又はその製薬上許容される塩を有効成分として含有する医薬組成物;
[A7] 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療のための[A1]から[A4]に記載の化合物若しくはそのプロドラッグ又はその製薬上許容される塩;
[A8] 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療のための医薬組成物を製造するための[A1]から[A4]に記載の化合物若しくはそのプロドラッグ又はその製薬上許容される塩の使用;
[A9] 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療の方法であって、下記一般式(I)で表される化合物若しくはそのプロドラッグ又はその製薬上許容される塩を対象に投与することを含む方法;
[A10] 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療の方法であって、
[A11] 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療の方法であって、下記一般式(III)で表される化合物若しくはそのプロドラッグ又はその製薬上許容される塩を対象に投与することを含む方法;
[A12] 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療の方法であって、
[A13] 精神神経疾患が、ダウン症候群、アルツハイマー病、及び/又はダウン症候群において発症しうるアルツハイマー病である、[A1]から[A12]のいずれかに記載の化合物若しくはそのプロドラッグ若しくはその塩、医薬組成物、使用、又は方法。
[A14] 悪性腫瘍が、脳腫瘍、グリオブラストーマ、膵管がん、横紋筋肉腫、肺がん、すい臓がん、大腸がん、皮膚がん、前立腺がん、乳がん、及びは、卵巣がんからなる群から選択される悪性腫瘍である、[A1]から[A12]のいずれかに記載の化合物若しくはそのプロドラッグ若しくはその塩、医薬組成物、使用、又は方法。
[A15] 悪性腫瘍が、既存薬耐性悪性腫瘍、レセプター型チロシンキナーゼ活性を抑制又は阻害することにより予防、改善、進行抑制、及び/又は、治療ができると知られ又は今後知られる悪性腫瘍、上皮成長因子受容体(EGFR)チロシンキナーゼ活性を抑制又は阻害することにより予防、改善、進行抑制、及び/又は、治療ができると知られ又は今後知られる悪性腫瘍、レセプター型チロシンキナーゼ若しくは上皮成長因子受容体(EGFR)チロシンキナーゼの活性を阻害する薬剤では予防、改善、進行抑制、及び/又は、治療の有意な効果は見られないと知られている又は今後知られる悪性腫瘍、並びに、ゲフィチニブでは予防、改善、進行抑制、及び/又は、治療の有意な効果は見られないと知られ又は今後知られる悪性腫瘍からなる群から選択される悪性腫瘍である、[A1]から[A12]のいずれかに記載の化合物若しくはそのプロドラッグ若しくはその塩、医薬組成物、使用、又は方法。
本開示は、一又は複数の実施形態において、下記一般式(II)で表される化合物若しくはそのプロドラッグ又はその製薬上許容される塩に関する。
一般式(II)で表される化合物若しくはそのプロドラッグ又はその製薬上許容される塩が精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療に効果を示す。そのメカニズムは以下のように推定される。すなわち、一般式(II)で表される化合物又はその製薬上許容される塩は、タウ蛋白質(Tau)の異常リン酸化を抑制でき、加えてアミロイド前駆体蛋白質(APP)のリン酸化を抑制することによりアミロイドベータ(Aβ)ペプチドの産生を抑制でき、それにより、精神神経疾患の予防、改善、進行抑制、及び/又は、治療しうると推定される。さらに、そのリン酸化酵素活性阻害効果により悪性腫瘍を予防、改善、進行抑制、及び/又は、治療しうると推定される。但し、本開示はこの推定に限定して解釈されなくてもよい。また、一般式(II)で表される化合物若しくはそのプロドラッグ又はその製薬上許容される塩は、一又は複数の実施形態において、脳内移行性及び経口吸収性を発揮する。それにより、より効果的に精神神経疾患又は悪性腫瘍を予防、改善、進行抑制、及び/又は、治療しうる。
[B1] 下記一般式(II)で表される化合物若しくはそのプロドラッグ又はその製薬上許容される塩;
[B2]
[B3] [B1]又は[B2]に記載の化合物若しくはそのプロドラッグ又はその製薬上許容される塩を有効成分として含有する医薬組成物;
[B4] 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療のための医薬組成物であって、[B1]又は[B2]に記載の化合物若しくはそのプロドラッグ又はその製薬上許容される塩を有効成分として含有する医薬組成物;
[B5] 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療のための[B1]又は[B2]に記載の化合物若しくはそのプロドラッグ又はその製薬上許容される塩;
[B6] 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療のための医薬組成物を製造するための[B1]又は[B2]に記載の化合物若しくはそのプロドラッグ又はその製薬上許容される塩の使用;
[B7] 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療の方法であって、下記一般式(II)で表される化合物若しくはそのプロドラッグ又はその製薬上許容される塩を対象に投与することを含む方法;
[B8] 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療の方法であって、
[B9] 精神神経疾患が、ダウン症候群、アルツハイマー病、及び/又はダウン症候群において発症しうるアルツハイマー病である、[B1]から[B8]のいずれかに記載の化合物若しくはそのプロドラッグ若しくはその塩、医薬組成物、使用、又は方法。
[B10] 悪性腫瘍が、脳腫瘍、グリオブラストーマ、膵管がん、横紋筋肉腫、肺がん、すい臓がん、大腸がん、皮膚がん、前立腺がん、乳がん、及び、卵巣がんからなる群から選択される悪性腫瘍である、[B1]から[B8]のいずれかに記載の化合物若しくはそのプロドラッグ若しくはその塩、医薬組成物、使用、又は方法。
[B11] 悪性腫瘍が、既存薬耐性悪性腫瘍、レセプター型チロシンキナーゼ活性を抑制又は阻害することにより予防、改善、進行抑制、及び/又は、治療ができると知られ又は今後知られる悪性腫瘍、上皮成長因子受容体(EGFR)チロシンキナーゼ活性を抑制又は阻害することにより予防、改善、進行抑制、及び/又は、治療ができると知られ又は今後知られる悪性腫瘍、レセプター型チロシンキナーゼ若しくは上皮成長因子受容体(EGFR)チロシンキナーゼの活性を阻害する薬剤では予防、改善、進行抑制、及び/又は、治療の有意な効果は見られないと知られている又は今後知られる悪性腫瘍、並びに、ゲフィチニブでは予防、改善、進行抑制、及び/又は、治療の有意な効果は見られないと知られ又は今後知られる悪性腫瘍からなる群から選択される悪性腫瘍である、[B1]から[B8]のいずれかに記載の化合物若しくはそのプロドラッグ若しくはその塩、医薬組成物、使用、又は方法。
TLC Rf = 0.50 (n-hexane/EtOAc = 6/1)
TLC Rf = 0.40 (n-hexane/EtOAc = 3/1)
TLC Rf = 0.30 (n-hexane/EtOAc = 1/1)
1H NMR (400 MHz, CDCl3) δ(6.94 (dd, J = 8.4, 8.4 Hz, 1H), 6.28 (dd, J = 0.4, 7.6 Hz, 1H), 6.23 (dd, J = 0.4, 7.6 Hz, 1H), 4.59 (t, J = 8.4 Hz, 2H), 3.60 (brs, 2H), 3.02 (t, J = 8.4 Hz, 2H)。
TLC Rf = 0.15 (n-hexane/EtOAc = 1/1)
1H NMR (400 MHz, CDCl3) δ 7.18 (d, J = 6.4 Hz, 1H), 7.09 (t, J = 6.4 Hz, 1H), 7.04 (brs, 1H), 6.62 (d, J = 6.0 Hz, 1H), 4.59 (t, J = 6.8 Hz, 2H), 3.13 (t, J = 6.8 Hz, 2H), 2.18 (s, 3H)。
TLC Rf = 0.25 (n-hexane/EtOAc = 1/1)
1H NMR (400 MHz, CDCl3) δ 7.29 (d, J = 8.4 Hz, 1H), 7.11 (brs, 1H), 6.58 (d, J = 8.4 Hz, 1H), 4.60 (t, J = 8.8 Hz, 2H), 3.22 (t, J = 8.8 Hz, 2H), 2.23 (s, 3H)
TLC Rf = 0.35 (n-hexane/EtOAc = 1/1)
1H NMR (400 MHz, CDCl3) for a mixture of two rotamers (70 : 30) δ 8.85 (brs, 0.3H), 8.33 (brs, 0.7H), 7.41 (d, J = 8.8 Hz, 0.3H), 7.36 (d, J = 8.4 Hz, 0.7H), 6.73 (d, J = 8.8 Hz, 0.3H), 6.69 (d, J = 8.4 Hz, 0.7H), 4.69−4.59 (m, 2H), 3.19−3.27 (m, 2H), 2.76 (s, 2.1H), 2.36 (s, 0.9H)。
TLC Rf = 0.25 (n-hexane/EtOAc = 1/1)
1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 8.4 Hz, 1H), 6.82 (d, J = 8.4 Hz, 1H), 4.63 (t, J = 8.8 Hz, 2H), 3.51 (t, J = 8.8 Hz, 2H), 2.75 (s, 3H)。
TLC a tailing spot Rf = 0.25 (CH2Cl2/MeOH = 5/1)
1H NMR (400 MHz, CD3OD) δ 8.00 (d, J = 8.8 Hz, 1H), 3.17 (s, 3H), 7.27 (d, J = 8.8 Hz, 1H), 4.82 (t, J = 8.8 Hz, 2H), 4.76 (q, J = 7.2 Hz, 2H), 3.86 (t, J = 8.8 Hz, 2H), 1.59 (t, J = 7.2 Hz, 3H)。
TLC Rf = 0.25 (n-hexane/EtOAc = 1/1)
mp 226−227 ℃
1H NMR (500 MHz, CDCl3) δ 7.29 (d, J = 8.5 Hz, 1H), 6.67 (d, J = 8.5 Hz, 1H), 5.84 (s, 1H), 4.65 (t, J = 8.5 Hz, 2H), 4.12 (q, J = 7.0 Hz, 2H), 3.55 (t, J = 8.5 Hz, 2H), 2.23 (s, 3H), 1.40 (t, J = 7.0 Hz, 3H)。
1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 8.8 Hz, 1H), 6.74 (brs, 2H), 6.11 (d, J = 8.8 Hz, 1H), 4.75 (s, 2H), 3.88 (s, 3H)。
1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 8.8 Hz, 1H), 6.28 (d, J = 8.8 Hz, 1H), 5.78 (brs, 2H), 4.63 (s, 2H)。
1H NMR (400 MHz, CDCl3) δ 7.28 (d, J = 8.4 Hz, 1H), 6.18 (d, J = 8.4 Hz, 1H), 5.42 (brs, 1H), 4.64−4.60 (m, 1H), 4.42−4.39 (m, 3H), 1.81 (brs, 1H)。
1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 2.4 Hz, 1H), 7.30 (d, J = 8.8 Hz, 1H), 6.84 (d, J = 8.8 Hz, 1H), 6.67 (d, J = 2.4 Hz, 1H), 4.33−4.29 (brs, 2H)。
1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 2.0 Hz, 1H), 7.49 (brs, 1H), 7.42 (d, J = 8.8 Hz, 1H), 7.23 (d, J = 8.8 Hz, 1H), 6.73 (d, J = 2.0 Hz, 1H), 2.27 (s, 3H)。
1H NMR (300 MHz, DMSO-d6) δ 11.60 (brs, 1H), 8.01 (d, J = 2.1 Hz, 1H), 7.56 (s, 2H), 6.77 (d, J = 2.1 Hz, 1H), 2.66 (s, 3H)。
1H NMR (300 MHz, CDCl3) δ 7.73 (d, J = 2.1 Hz, 1H), 7.67 (d, J = 8.7 Hz, 1H), 7.53 (d, J = 8.7 Hz, 1H), 7.28 (d, J = 2.1 Hz, 1H), 2.90 (s, 3H)。
1H NMR (400 MHz, DMSO-d6) δ 8.49 (d, J = 2.1 Hz, 1H), 8.36 (d, J = 8.8 Hz, 1H), 8.16 (d, J = 8.8 Hz, 1H), 7.77 (d, J = 2.1 Hz, 1H), 4.90 (q, J = 7.2 Hz, 2H), 3.26 (s, 3H), 1.53 (t, J = 7.2 Hz, 3H)。
1H NMR (400 MHz, CDCl3) δ 7.71 (t, J = 1.2 Hz, 1H), 7.44 (d, J = 8.8 Hz, 1H), 7.33 (dd, J = 8.8, 0.9 Hz, 1H), 6.94 (dd, J = 2.1, 0.9 Hz,1H), 5.92 (s, 1H), 4.27 (q, J = 7.2 Hz, 2H), 2.24 (s, 3H), 1.47 (t, J = 7.2 Hz, 3H)。
TLC Rf = 0.35 (n-hexane/EtOAc = 5/1)
1H NMR (500 MHz, CDCl3) δ 7.68 (d, J = 9.0 Hz, 1H, aromatic), 7.02 (d, J = 9.0 Hz, 1H, aromatic), 3.98 (s, 3H, OCH3), 2.87 (s, 3H, ArCH3)。
13C NMR (126 MHz, CDCl3) δ 169.7, 154.9, 153.1, 128.2, 120.3, 110.5, 104.7, 57.2, 20.5。
TLC Rf = 0.35 (n-hexane/EtOAc = 5/1)*
*TLC Rf = 0.45 (triple or quadruple development with n-hexane/EtOAc = 10/1), cf. TLC of 3a: Rf = 0.40 (triple or quadruple development with n-hexane/EtOAc = 10/1)
IR (KBr, cm-1) 3404, 3057, 2937, 1459, 1395, 1275, 1216, 1100, 749, 642。
1H NMR (500 MHz, CDCl3) δ 7.79 (d, J = 8.5 Hz, 1H, aromatic), 7.53−7.51 (m, 1H, aromatic), 7.39−7.33 (m, 3H, aromatic), 7.11 (d, J = 8.5 Hz, 1H, aromatic), 3.83 (s, 3H, OCH3), 2.74 (s, 3H, hetArCH3)。
13C NMR (126 MHz, CDCl3) δ 168.2, 155.5, 153.3, 134.8, 134.4, 132.4, 129.4, 128.9, 128.2, 126.4, 121.8, 121.2, 110.0, 56.8, 20.5。
IR (KBr, cm-1) 3404, 3057, 2937, 1459, 1395, 1275, 1216, 1100, 749, 642。
1H NMR (500 MHz, DMSO-d6) δ 8.52 (d, J = 9.0 Hz, 1H, aromatic), 7.74−7.67 (m, 2H, aromatic), 7.61−7.50 (m, 3H, aromatic), 4.15−4.06 (m, 1H, NCHgem-AA'CH3), 3.98−3.90 (m, 1H, NCHgem-AA'CH3), 3.81 (s, 3H, OCH3), 3.12 (s, 3H, hetArCH3) 0.99 (t, J = 7.0 Hz, 3H, CH2CH3)。
13C NMR (126 MHz, DMSO-d6) δ 179.0, 158.2, 138.6, 133.9, 132.7, 131.2, 130.7, 129.6, 127.5, 125.8, 121.9, 120.7 (q, J = 324 Hz), 116.1, 113.4, 57.2, 45.6, 17.3, 13.1。
TLC Rf = 0.30 (n-hexane/EtOAc = 1/1)
IR (KBr, cm-1) 2935, 2839, 1458, 1424, 1194, 1091, 1044, 969, 765。
1H NMR (500 MHz, CDCl3) δ 7.55−7.50 (m, 2H, aromatic), 7.42−7.31 (m, 3H, aromatic), 6.84 (d, J = 9.0 Hz, 1H, aromatic), 5.78 (s, 1H, olefinic), 3.72 (s, 3H, OCH3), 3.65−3.46 (m, 2H, CH2CH3), 2.21 (s, 3H, C(O)CH3), 0.93 (t, J = 7.2 Hz, 3H, CH2CH3)。
13C NMR (126 MHz, CDCl3) δ 191.1, 161.6, 156.8, 137.5, 135.3, 134.0, 132.2, 129.6, 129.4, 126.6, 122.3, 120.3, 112.9, 106.3, 90.7, 56.7, 41.9, 29.1, 11.9。
TLC Rf = 0.20 (n-hexane/EtOAc = 1/1, broad spot)
IR (KBr, cm-1) 3118, 1473, 1420, 1287, 991, 814, 765。
1H NMR (500 MHz, DMSO-d6) δ 9.62 (s, 1H, ArOH), 7.59 (d, J = 8.0 Hz, 1H, aromatic), 7.54 (d, J = 8.5 Hz, 1H, aromatic), 7.48−7.40 (m, 3H, aromatic), 6.80 (d, J = 8.5 Hz, 1H, aromatic), 5.93 (s, 1H, olefinic), 3.63−3.55 (m, 1H, CHAA'-GemCH3), 3.46−3.38 (m, 1H, CHAA'-GemCH3), 2.05 (s, 3H, C(O)CH3), 0.81 (t, J = 7.0 Hz, 3H, CH2CH3)。
13C NMR (126 MHz, DMSO-d6) δ 189.9, 160.4, 155.2, 137.4, 134.7, 134.4, 133.2, 130.4, 129.5, 127.5, 122.9, 116.9, 111.5, 111.0, 90.7, 41.7, 29.2, 12.1。
TLC Rf = 0.30 (n-hexane/EtOAc = 1/1)
mp 190−192 ℃
IR (KBr, cm-1) 3058, 2987, 2931, 1346, 1203, 1011, 741, 647, 542。
1H NMR (500 MHz, CDCl3) δ 8.07 (d, J = 8.5 Hz, 1H, aromatic), 7.67−7.64 (m, 2H, aromatic), 7.52 (dd, J = 8.0, 1.5 Hz, 1H, aromatic), 7.46−7.39 (m, 2H, aromatic), 6.05 (s, 1H, olefinic), 4.69 (q, J = 7.0 Hz, 2H, CH2CH3), 2.30 (s, 3H, C(O)CH3), 1.75 (t, J = 7.0 Hz, 3H, CH2CH3)。
13C NMR (126 MHz, CDCl3) δ 191.1, 160.7, 156.7, 156.1, 135.2, 127.2, 123.3, 122.6, 121.4, 121.3, 121.1, 112.4, 109.3, 107.0, 90.2, 43.7, 29.1, 14.4。
アルゴン雰囲気下、2,3-ジヒドロベンゾフラン-5-カルバルデヒド(296 mg, 2.00 mmol, 商用品)、酢酸アンモニウム(NH4OAc)(77.0 mg, 1.00 mmol, 商用品)、ロダニン(rhodanine)(266 mg, 2.00 mmol, 商用品)のアセトニトリル(MeCN)(2 mL, 脱水, 商用品)溶液に、酢酸(AcOH)(120 μL, 2.10 mmol, 商用品)を室温にて添加し、混合物を3.5時間加熱還流した。室温まで放冷した後、析出した結晶を桐山ロートで濾過、水(3 mL x 4)、ジエチルエーテル(3 mL x 2)で洗浄し、(Z)-5-[(2,3-ジヒドロベンゾフラン-5-イル)メチレン]-2-チオキソチアゾリジン-4-オン ((Z)-5-[(2,3-dihydrobenzofuran-5-yl)methylene]-2-thioxothiazolidin-4-one)(化合物4)(488 mg, 1.86 mmol, 92.7%)を黄色の固体として得た。
mp 247−248 ℃
1H NMR (400 MHz, DMSO-d6) δ 13.70 (brs, 1H), 7.58 (s, 1H), 7.47 (s, 1H), 7.41 (d, J = 8.4 Hz, 1H), 6.93 (d, J = 8.4 Hz, 1H), 4.63 (t, J = 8.4 Hz, 2H), 3.25 (t, J = 8.4 Hz, 2H)。
アルゴン雰囲気下、ベンゾフラン-5-カルバルデヒド(146 mg, 1.00 mmol, J. Med. Chem., 2009, 52, 6270−6286. に従い合成)、酢酸アンモニウム(NH4OAc)(38.5 mg, 0.500 mmol, 商用品)、ロダニン(rhodanine)(133 mg, 1.00 mmol, 商用品)のアセトニトリル(MeCN)(2 mL, 脱水, 商用品)溶液に、酢酸(AcOH)(60 μL, 1.1 mmol, 商用品)を室温にて添加し、混合物を2時間加熱還流した。室温まで放冷した後、析出した結晶を桐山ロートで濾過、水(3 mL x 4)、ジエチルエーテル(3 mL x 2)で洗浄し、(Z)-5-[(ベンゾフラン-5-イル)メチレン]-2-チオキソチアゾリジン-4-オン ((Z)-5-[(benzofuran-5-yl)methylene]-2-thioxothiazolidin-4-one)(化合物5)(212 mg, 0.812 mmol, 81.2%)を黄色の固体として得た。
mp 264−265 ℃
1H NMR (400 MHz, DMSO-d6) δ 13.84 (brs, 1H), 8.13 (d, J = 2.0 Hz, 1H), 7.96 (d, J = 2.0 Hz, 1H), 7.81−7.78 (m, 2H), 7.61 (dd, J = 8.8, 2.0 Hz, 1H), 7.12 (d, J = 2.0 Hz, 1H).
アルゴン雰囲気下、ジベンゾフラン-2-カルバルデヒド(196 mg, 0.999 mmol, Eur. J. Med. Chem. 2011, 46, 4827−4833. に従い合成)、酢酸アンモニウム(NH4OAc)(38.5 mg, 0.499 mmol, 商用品)、ロダニン(rhodanine)(133 mg, 0.999 mmol, 商用品)のアセトニトリル(MeCN)(脱水, 2 mL, 商用品)溶液に、酢酸(AcOH)(57 μL, 1.0 mmol, 商用品)を室温にて添加し、混合物を2時間加熱還流した。室温まで放冷した後、析出した結晶を桐山ロートで濾過、水(3 mL x 4)、ジエチルエーテル(3 mL x 2)で洗浄し、(Z)-5-[(ジベンゾフラン-2-イル)メチレン]-2-チオキソチアゾリジン-4-オン((Z)-5-(dibenzo[b,d]furan-2-ylmethylene)-2-thioxothiazolidin-4-one)(化合物6)(351 mg, >0.999 mmol, >100%, 純度 約85%)を薄黄色の固体として得た。
mp 287−288 ℃
1H NMR (400 MHz, DMSO-d6) δ 13.85 (brs, 1H, NH), 8.37 (s, 1H, aromatic), 8.29 (d, J = 7.2 Hz, 1H, aromatic), 7.88 (d, J = 8.4 Hz, 1H, aromatic), 7.82 (s, 1H, olefinic), 7.80−7.74 (m, 2H, aromatic), 7.60 (dd, J = 8.4, 0.8 Hz, 1H, aromatic), 7.45 (dd, J = 8.4, 1.2 Hz, 1H, aromatic)。
アルゴン雰囲気下、2,3-ジヒドロベンゾフラン-5-カルバルデヒド(296 mg, 2.00 mmol, 商用品)、酢酸アンモニウム(NH4OAc)(77.0 mg, 1.00 mmol, 商用品)、シュードチオヒダントイン(pseudothiohydantoin)(232 mg, 2.00 mmol, 商用品)のアセトニトリル(MeCN)(2 mL, 脱水, 商用品)溶液に、酢酸(AcOH)(120 μL, 2.10 mmol, 商用品)を室温にて添加し、混合物を6時間加熱還流した。室温まで放冷した後、析出した結晶を桐山ロートで濾過、水(3 mL x 4)、ジエチルエーテル(3 mL x 2)で洗浄し、(Z)-5-[(2,3-ジヒドロベンゾフラン-5-イル)メチレン]-2-イミノチアゾリジン-4-オン ((Z)-5-[(2,3-dihydrobenzofuran-5-yl)methylene]-2-iminothiazolidin-4-one)(化合物7)(468 mg, 1.90 mmol, 95.1%)を薄黄色の固体として得た。
mp 280 ℃ (dec)
1H NMR (400 MHz, DMSO-d6) δ 9.33 (brs, 1H), 9.07 (brs, 1H), 7.55 (s, 1H), 7.46 (s, 1H), 7.36 (dd, J = 7.2, 0.8 Hz, 1H), 6.92 (d, J = 7.2 Hz, 1H), 4.62 (t, J = 7.2 Hz, 2H), 3.26 (t, J = 7.2 Hz, 2H)。
アルゴン雰囲気下、ベンゾフラン-5-カルバルデヒド(146 mg, 1.00 mmol, J. Med. Chem., 2009, 52, 6270−6286. に従い合成)、酢酸アンモニウム(NH4OAc)(38.5 mg, 0.500 mmol, 商用品)、シュードチオヒダントイン(pseudothiohydantoin)(133 mg, 1.00 mmol, 商用品)のアセトニトリル(MeCN)(2 mL, 脱水, 商用品)溶液に、酢酸(AcOH)(60 μL, 1.1 mmol, 商用品)を室温にて添加し、混合物を2時間加熱還流した。室温まで放冷した後、析出した結晶を桐山ロートで濾過、水(3 mL x 4)、ジエチルエーテル(3 mL x 2)で洗浄し、 (Z)-5-[(ベンゾフラン-5-イル)メチレン]-2-イミノチアゾリジン-4-オン ((Z)-5-[(benzofuran-5-yl)methylene]-2-iminothiazolidin-4-one)(化合物8)(94.8 mg, 0.389 mmol, 38.9%)を薄黄色の固体として得た。
mp 250 ℃ (dec)
1H NMR (400 MHz, DMSO-d6) δ 9.43 (brs, 1H), 9.17 (brs, 1H), 8.13 (d, J = 2.0 Hz, 1H), 7.93 (d, J = 2.0 Hz, 1H), 7.79−7.76 (m, 2H), 7.59 (dd, J = 8.8, 2.0 Hz, 1H), 7.11 (d, J = 2.0 Hz, 1H)。
アルゴン雰囲気下、ジベンゾフラン-2-カルバルデヒド(196 mg, 0.999 mmol, Eur. J. Med. Chem. 2011, 46, 4827−4833. に従い合成)、酢酸アンモニウム(NH4OAc)(38.5 mg, 0.499 mmol, 商用品)、シュードチオヒダントイン(pseudothiohydantoin)(133 mg, 1.15 mmol, 商用品)のアセトニトリル(MeCN)(脱水, 2 mL, 商用品)溶液に、酢酸(AcOH)(57 μL, 1.0 mmol,商用品)を室温にて添加し、混合物を2時間加熱還流した。室温まで放冷した後、析出した結晶を桐山ロートで濾過、水(3 mL x 4)、ジエチルエーテル(3 mL x 2)で洗浄し、(Z)-5-[(ジベンゾフラン-5-イル)メチレン]-2-イミノチアゾリジン-4-オン ((Z)-5-(dibenzo[b,d]furan-2-ylmethylene)-2-iminothiazolidin-4-one)(化合物9)(263 mg, 0.894 mmol, 89.5%, 純度 約85%)を薄黄色の固体として得た。
mp 290−291 ℃ (dec).
1H NMR (400 MHz, DMSO-d6) δ 9.43 (brs, 1H, NH), 9.17 (brs, 1H, NH), 8.35 (s, 1H, aromatic), 8.17 (d, J = 6.8 Hz, 1H, aromatic), 7.85 (d, J = 7.2 Hz, 1H, aromatic), 7.77 (s, 1H, olefinic), 7.75−7.71 (m, 2H, aromatic), 7.58 (dd, J = 8.0, 1.2 Hz, 1H, aromatic), 7.46 (dd, J = 8.0, 0.8 Hz, 1H, aromatic)。
TLC Rf = 0.40 (n-hexane/EtOAc = 20/1)
1H NMR (400 MHz, CDCl3) δ 7.45 (s, 1H, aromatic), 7.13 (s, 1H, aromatic), 2.23 (s, 3H, ArCH3), 2.21 (s, 3H, ArCH3), 1.36 (s, 12H, (CH3)2C−C(CH3)2)。
TLC Rf = 0.40 (n-hexane/EtOAc = 5/1)
1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.8 Hz, 1H, aromatic), 7.31 (s, 1H, aromatic), 7.16 (s, 1H, aromatic), 7.11 (d, J = 8.8, 1H, aromatic), 3.84 (s, 3H, OCH3), 2.75 (s, 3H, hetArCH3), 2.30 (s, 3H, ArCH3), 2.28 (s, 3H, ArCH3)。
1H NMR (400 MHz, CDCl3) δ 8.06 (d, J = 8.8 Hz, 1H, aromatic), 7.42 (d, J = 8.8 Hz, 1H, aromatic), 7.32 (s, 1H, aromatic), 7.27 (s, 1H, aromatic), 4.28 (q, J = 7.2 Hz, 2H, CH2CH3), 3.86 (s, 3H, OCH3), 3.19 (s, 3H, hetArCH3), 2.35 (s, 3H, ArCH3), 2.30 (s, 3H, ArCH3), 1.14 (t, J = 7.2 Hz, 3H, CH2CH3)。
TLC Rf = 0.35 (n-hexane/EtOAc = 1/1)
1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 8.8 Hz, 1H, aromatic), 7.28 (s, 1H, aromatic), 7.06 (s, 1H, aromatic), 6.82 (d, J = 8.8 Hz, 1H, aromatic), 5.77 (s, 1H, olefinic), 3.72 (s, 3H, OCH3), 3.62−3.49 (m, 2H, CH2CH3), 2.32 (s, 3H, ArCH3), 2.26 (s, 3H, ArCH3), 2.21 (s, 3H, C(O)CH3), 0.95 (t, J = 7.2 Hz, 3H, CH2CH3)。
TLC Rf = 0.20 (CH2Cl2/MeOH = 20/1)
1H NMR (400 MHz, DMSO-d6) δ 9.53 (s, 1H, ArOH), 7.50 (d, J = 8.4, 1H, aromatic), 7.35 (s, 1H, aromatic), 7.20 (s, 1H, aromatic), 6.78 (d, J = 8.4 Hz, 1H, aromatic), 5.91 (s, 1H, olefinic), 3.66−3.56 (m, 1H, CHAA'-GemCH3), 3.51−3.41 (m, 1H, CHAA'-GemCH3), 2.29 (s, 3H, ArCH3), 2.23 (s, 3H, ArCH3), 2.06 (s, 3H, C(O)CH3), 0.84 (t, J = 6.8 Hz, 3H, CH2CH3)。
TLC Rf = 0.40 (n-hexane/EtOAc = 1/1)
mp 263−265 ℃
IR (KBr cm-1) 3074, 2977, 2941, 1607, 1506, 1489, 1330, 1316, 1115, 975, 863, 802, 777。
1H NMR (500 MHz, CDCl3) δ 7.72 (s, 1H, aromatic), 7.54 (d, J = 8.5 Hz, 1H, aromatic), 7.38 (s, 1H, aromatic), 7.35 (d, J = 8.5 Hz, 1H, aromatic), 6.00 (s, 1H, olefinic), 4.60 (q, 2H, J = 6.5 Hz, CH2CH3), 2.41 (s, 6H, ArCH3×2), 2.29 (s, 3H, C(O)CH3), 1.70 (t, J = 6.5 Hz, 3H, CH2CH3)。
13C NMR (126 MHz, CDCl3) δ 190.9, 160.7, 156.6, 154.9, 136.7, 134.9, 131.5, 122.9, 121.0, 120.2, 118.8, 112.6, 109.3, 106.9, 90.0, 43.5, 29.0, 20.6, 20.4, 14.3。
TLC Rf = 0.40 (n-hexane/EtOAc = 5/1)
1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.8 Hz, 1H, aromatic), 7.35 (d, J = 0.8 Hz, 1H, aromatic), 7.27 (d, J = 7.6 Hz, 1H, aromatic), 7.17 (d, J = 7.6, 0.8 Hz, 1H, aromatic), 7.10, (d, J = 8.8 Hz, 1H, aromatic), 3.83 (s, 3H, OCH3), 2.74 (s, 3H, hetArCH3), 2.40 (s, 3H, ArCH3)。
1H NMR (400 MHz, CDCl3) δ 8.09 (d, J = 9.2 Hz, 1H, aromatic), 7.44−7.41 (m, 3H, aromatic), 7.28 (d, J = 9.2 Hz, 1H, aromatic), 4.28 (q, 2H, J = 7.2 Hz, CH2CH3), 3.85 (s, 3H, OCH3), 3.18 (s, 3H, hetArCH3), 2.46 (s, 3H, ArCH3), 1.13 (t, J = 7.2 Hz, 3H, CH2CH3)。
TLC Rf = 0.30 (n-hexane/EtOAc = 1/1)
1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 8.4 Hz, 1H, aromatic), 7.34 (s, 1H, aromatic), 7.21−7.14 (m, 2H, aromatic), 6.83 (d, J = 8.4 Hz, 1H, aromatic), 5.78 (s, 1H, olefinic), 3.72 (s, 3H, OCH3), 3.65−3.48 (m, 2H, CH2CH3), 2.43 (s, 3H, C(O)CH3), 2.21 (s, 3H, ArCH3), 0.95 (t, J = 7.2 Hz, 3H, CH2CH3)。
1H NMR (400 MHz, DMSO-d6) δ 9.55 (s, 1H, ArOH), 7.52 (d, J = 8.4 Hz, 1H, aromatic), 7.42 (s, 1H, aromatic), 7.32 (d, J = 8.4 Hz, 1H, aromatic), 7.23 (d, J = 8.4 Hz, 1H, aromatic), 6.79 (d, J = 8.4 Hz, 1H, aromatic), 5.92 (s, 1H, olefinic), 3.67−3.57 (m, 1H, CHAA'-GemCH3), 3.53−3.41 (m, 1H, CHAA'-GemCH3), 2.38 (s, 3H, ArCH3), 2.06 (s, 3H, C(O)CH3), 0.83 (t, J = 7.2 Hz, 3H, CH2CH3)。
TLC Rf = 0.25 (n-hexane/EtOAc = 1/1)
mp 204−205 ℃
IR (KBr, cm-1) 3062, 2970, 2360, 1606, 1470, 1187, 1014, 805, 723。
1H NMR (500 MHz, CDCl3) δ 7.90 (d, J = 8.5 Hz, 1H, aromatic), 7.60 (d, J = 8.0 Hz, 1H, aromatic), 7.45 (s, 1H, aromatic), 7.41 (d, J = 8.0 Hz, 1H, aromatic), 7.21, (d, J = 8.5 Hz, 1H, aromatic), 6.04 (s, 1H, olefinic), 4.66 (q, J = 7.0 Hz, 2H, CH2CH3), 2.55 (s, 3H, ArCH3), 2.30 (s, 3H, C(O)CH3), 1.72 (t, J = 7.0 Hz, 3H, CH2CH3)。
13C NMR (126 MHz, CDCl3) δ 191.1, 160.7, 156.6, 156.5, 137.9, 134.9, 124.6, 122.1, 121.2, 120.5, 118.6, 112.5, 109.3, 107.0, 90.1, 43.6, 29.1, 21.6, 14.3。
TLC Rf = 0.40 (n-hexane/EtOAc = 5/1)
1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.8 Hz, 1H, aromatic), 7.39 (d, J = 8.0 Hz, 1H, aromatic), 7.18−7.12 (m, 2H, aromatic), 7.10 (d, J = 8.8 Hz, 1H, aromatic), 3.83 (s, 3H, OCH3), 2.74 (s, 3H, hetArCH3), 2.37 (s, 3H, ArCH3)。
1H NMR (400 MHz, CDCl3) δ 8.08 (d, J = 9.2 Hz, 1H, aromatic), 7.45−7.41 (m, 2H, aromatic), 7.34−7.26 (m, 2H, aromatic), 4.31−4.21 (m, 2H, NCH2CH3), 3.86 (s, 3H, OCH3), 3.18 (s, 3H, hetArCH3), 2.41 (s, 3H, ArCH3), 1.13 (t, J = 7.2 Hz, 3H, NCH2CH3)。
1H NMR (400 MHz, CDCl3) δ 7.53 (d, J = 8.4 Hz, 1H, aromatic), 7.38 (d, J = 8.0 Hz, 1H, aromatic), 7.19 (dd, J = 8.0, 2.0 Hz, 1H, aromatic), 7.12 (d, J = 0.8 Hz, 1H, aromatic), 6.83 (d, J = 8.4 Hz, 1H, aromatic), 5.78 (s, 1H, olefinic), 3.73 (s, 3H, OCH3), 3.60−3.47 (m, 2H, NCH2CH3), 2.37 (s, 3H, ArCH3), 2.22 (s, 3H, C(O)CH3), 0.95 (t, J = 7.2 Hz, 3H, NCH2CH3)。
TLC Rf = 0.30 (CH2Cl2/MeOH = 20/1)
1H NMR (400 MHz, DMSO-d6) δ 9.57 (s, 1H, ArOH), 7.52 (d, J = 8.4 Hz, 1H, aromatic), 7.45 (d, J = 8.8 Hz, 1H, aromatic), 7.28−7.26 (m, 2H, aromatic), 6.80 (d, J = 8.4 Hz, 1H, aromatic), 5.92 (s, 1H, olefinic), 3.63−3.56 (m, 1H, NCHgem-AA'CH3), 3.47−3.39 (m, 1H, NCHgem-AA'CH3), 2.32 (s, 3H, ArCH3), 2.06 (s, 3H, C(O)CH3), 0.83 (t, J = 6.8 Hz, 3H, NCH2CH3)。
TLC Rf = 0.30 (n-hexane/EtOAc = 1/1)
mp 191−192 ℃
IR (KBr, cm-1) 3357, 2973, 2921, 2360, 1610, 1360, 1193, 1013, 803。
1H NMR (500 MHz, CDCl3) δ 7.84 (s, 1H, aromatic), 7.63 (d, J = 8.5 Hz, 1H, aromatic), 7.54 (d, J = 8.5 Hz, 1H, aromatic), 7.43 (d, J = 8.5 Hz, 1H, aromatic), 7.34, (d, J = 8.5 Hz, 1H, aromatic), 6.05 (s, 1H, olefinic), 4.68 (q, 2H, J = 7.0 Hz, CH2CH3), 2.56 (s, 3H, ArCH3), 2.31 (s, 3H, C(O)CH3), 1.75 (t, J = 7.0 Hz, 3H, CH2CH3)。
13C NMR (126 MHz, CDCl3) δ 191.1, 160.8, 156.9, 154.4, 135.2, 132.5, 128.2, 122.7, 121.2, 121.1, 120.9, 111.8, 109.3, 107.0, 90.2, 43.7, 29.1, 22.0, 14.4。
TLC Rf = 0.45 (n-hexane/EtOAc = 5/1)
1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 8.8 Hz, 1H, aromatic), 7.50 (s, 1H, aromatic), 7.29 (s, 2H, aromatic), 7.02 (d, J = 8.8 Hz, 1H, aromatic), 3.75 (s, 3H, OCH3), 2.66 (s, 3H, hetArCH3)。
1H NMR (400 MHz, CDCl3) δ 8.12 (d, J = 9.2 Hz, 1H, aromatic), 7.58 (d, J = 2.4 Hz, 1H, aromatic), 7.54 (d, J = 8.4 Hz, 1H, aromatic), 7.48−7.41 (m, 2H, aromatic), 7.28 (d, J = 9.2 Hz, 1H, aromatic), 4.27 (q, J = 7.2 Hz, 2H, CH2CH3), 3.85 (s, 3H, OCH3), 3.16 (s, 3H, hetArCH3), 1.14 (t, J = 7.2 Hz, 3H, CH2CH3)。
TLC Rf = 0.30 (n-hexane/EtOAc = 1/1)
1H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 6.4 Hz, 1H, aromatic), 7.54 (s, 1H, aromatic), 7.37 (d, J = 6.4 Hz, 1H, aromatic), 7.27 (d, J = 6.4 Hz, 1H, aromatic), 6.83 (d, J = 6.4 Hz, 1H, aromatic), 5.80 (s, 1H, olefinic), 3.72 (s, 3H, OCH3), 3.64−3.48 (m, 2H, CH2CH3), 2.23 (s, 3H, C(O)CH3), 0.97 (t, J = 5.6 Hz, 3H, CH2CH3)。
TLC Rf = 0.20 (CH2Cl2/MeOH = 20/1)
1H NMR (400 MHz, DMSO-d6) δ 9.72 (s, 1H, ArOH), 7.78 (d, J = 1.2 Hz, 1H, aromatic), 7.57 (d, J = 8.4 Hz, 1H, aromatic), 7.52 (brs, 2H, aromatic), 6.82 (d, J = 8.4 Hz, 1H, aromatic), 5.96 (s, 1H, olefinic), 3.70−3.60 (m, 1H, CHAA'-GemCH3), 3.50−3.41 (m, 1H, CHAA'-GemCH3), 2.07 (s, 3H, C(O)CH3), 0.85 (t, J = 6.8 Hz, 3H, CH2CH3)。
TLC Rf = 0.35 (n-hexane/EtOAc = 1/1)
mp 224−225 ℃
IR (KBr, cm-1) 3066, 2970, 2928, 1607, 1589, 1270, 1125, 600, 500。
1H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 9.0 Hz, 1H, aromatic), 7.64 (s, 1H, aromatic), 7.63 (dd, J = 9.0, 1.5 Hz, 1H, aromatic), 7.41 (d, J = 8.5 Hz, 1H, aromatic), 7.37 (dd, J = 8.5, 1.5 Hz, 1H, aromatic), 6.04 (s, 1H, olefinic), 4.61 (q, J = 7.5 Hz, 2H, CH2CH3), 2.30 (s, 3H, C(O)CH3), 1.71 (t, J = 7.5 Hz, 3H, CH2CH3)。
13C NMR (126 MHz, CDCl3) δ 191.3, 160.6, 157.0, 156.3, 135.0, 132.8, 123.8, 123.1, 121.8, 121.4, 120.1, 112.8, 108.6, 106.9, 90.4, 43.6, 29.1, 14.3。
TLC Rf = 0.45 (n-hexane/EtOAc = 5/1)
1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 8.8 Hz, 1H, aromatic), 7.44 (d, J = 8.4 Hz, 1H, aromatic), 7.37 (d, J = 2.4 Hz, 1H, aromatic), 7.30 (dd, J = 8.4, 2.4 Hz, 1H, aromatic), 7.10, (d, J = 8.8 Hz, 1H, aromatic), 3.84 (s, 3H, OCH3), 2.75 (s, 3H, hetArCH3)。
1H NMR (400 MHz, CDCl3) δ 8.18 (d, J = 7.2 Hz, 1H, aromatic), 7.53−7.43 (m, 4H, aromatic), 4.32−4.17 (m, 2H, CH2CH3), 3.86 (s, 3H, OCH3), 3.18 (s, 3H, hetArCH3), 1.16 (t, J = 7.2 Hz, 3H, CH2CH3)。
TLC Rf = 0.30 (n-hexane/EtOAc = 1/1)
1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 7.6 Hz, 1H, aromatic), 7.45 (d, J = 8.8 Hz, 1H, aromatic), 7.39−7.33 (m, 2H, aromatic), 6.82 (d, J = 8.8 Hz, 1H, aromatic), 5.80 (s, 1H, olefinic), 3.73 (s, 3H, OCH3), 3.64−3.45 (m, 2H, CH2CH3), 2.22 (s, 3H, C(O)CH3), 0.99 (t, J = 7.2 Hz, 3H, CH2CH3)。
TLC Rf = 0.20 (CH2Cl2/MeOH = 20/1)
1H NMR (400 MHz, DMSO-d6) δ 9.72 (s, 1H, ArOH), 7.64−7.62 (m, 2H, aromatic), 7.57−7.53 (m, 2H, aromatic), 6.81 (d, J = 8.8 Hz, 1H, aromatic), 5.95 (s, 1H, olefinic), 3.68−3.58 (m, 1H, CHAA'-GemCH3), 3.47−3.30 (m, 1H, CHAA'-GemCH3), 2.07 (s, 3H, C(O)CH3), 0.87 (t, J = 6.8 Hz, 3H, CH2CH3)。
TLC Rf = 0.40 (n-hexane/EtOAc = 1/1)
mp 231−232 ℃
IR (KBr cm-1) 3099, 2962, 2360, 1485, 1201, 1013, 809, 773。
1H NMR (500 MHz, CDCl3) δ 7.99 (d, J = 2.0 Hz, 1H, aromatic), 7.65 (d, J = 8.5 Hz, 1H, aromatic), 7.56 (d, J = 8.5 Hz, 1H, aromatic), 7.47 (dd, J = 8.5, 2.0 Hz, 1H, aromatic), 7.41, (d, J = 8.5 Hz, 1H, aromatic), 6.05 (s, 1H, olefinic), 4.59 (q, 2H, J = 7.2 Hz, CH2CH3), 2.30 (s, 3H, C(O)CH3), 1.74 (t, J = 7.5 Hz, 3H, CH2CH3)。
13C NMR (126 MHz, CDCl3) δ 191.3, 160.6, 157.3, 154.4, 135.2, 128.7, 127.2, 122.7, 122.5, 121.9, 121.7, 113.2, 108.4, 107.0, 90.4, 43.7, 29.1, 14.4。
mp 291−292 ℃
1H NMR (400 MHz, DMSO-d6) δ 12.40 (brs, 1H, NH), 12.25 (brs, 1H, NH), 8.58 (d, J = 1.6 Hz, 1H, aromatic), 8.20 (d, J = 7.6 Hz, 1H, aromatic), 7.84 (dd, J = 8.8, 2.0 Hz, 1H, aromatic), 7.75−7.71 (m, 2H, aromatic), 7.59−7.54 (m, 1H, aromatic), 7.49−7.44 (m, 1H, aromatic), 6.67 (s, 1H, olefinic)。
製造例で合成した化合物について、tau蛋白質のリン酸化に対する抑制活性を下記の培養細胞を用いた評価系にて評価した。
評価系に使用する培養細胞として、tau蛋白質及びDYRK1A蛋白質をそれぞれ別個に発現誘導可能であり、かつ、DYRK1A蛋白質の活性依存的にtau蛋白質のリン酸価が評価可能な培養細胞を使用した。図1は、当該培養細胞に対するtau蛋白質の212番目のトレオニン残基のリン酸化を特異的に認識する抗体(上段)及びtau蛋白質を特異的に認識する抗体(下段)を用いたウエスタンブロッティングの結果の一例を示す。図1に示すとおり、当該培養細胞内では、tau蛋白質及びDYRK1A蛋白質がそれぞれ別個に発現可能であり、また、tau蛋白質は、DYRK1A蛋白質が存在することによりリン酸化が促進される。したがって、tau蛋白質及びDYRK1A蛋白質の双方を発現誘導し、tau蛋白質の212番目のトレオニン残基のリン酸化の程度を評価することで、tau蛋白質リン酸化抑制活性が評価できる。
上記評価系に10μMの化合物1、4、6−9を加え、tau蛋白質のリン酸化をtau蛋白質の212番目のトレオニン残基のリン酸化を特異的に認識する抗体により検出した。その結果の一例を図2に示す。図2は、10μMの化合物存在下でtau蛋白質及びDYRK1A蛋白質の双方を発現誘導した前記培養細胞について、tau蛋白質の212番目のトレオニン残基のリン酸化を特異的に認識する抗体を用いたウエスタンブロッティングを行った結果の一例を示す。なお、「control」は、化合物を加えない場合の結果を示す。対照化合物A−Cは、tau蛋白質のリン酸化阻害抑制効果がない対照化合物である。図2に示すとおり、化合物1、6、7、及び8は、強力なtau蛋白質リン酸化抑制効果を示した。また、化合物4及び9もtau蛋白質リン酸化抑制効果を示した。
化合物1について、下記条件で脳内移行性を評価した。その結果、血漿中濃度13.5μMの場合に、脳脊髄液中濃度1.88μMという結果を得た。すなわち、化合物1について脳内移行性が確認された。
[脳内移行性評価条件]
使用動物:wister rat ♂8週齢(約300 g)、尾静脈投与
投与溶媒:20 % PPG / 8 % tween80 / saline(2 ml / head)
化合物投与量:2 mg / head
採材時間:血漿:投与3分後 脳脊髄液:投与7 分後
分析試料:下大静脈から採血後の血漿、および、脳脊髄液
化合物1について、下記条件で経口吸収性を評価した。その結果の一例を図3に示す。図3に示すとおり、化合物1の経口吸収性が確認された。
[脳内移行性評価条件]
使用動物:B6J マウス ♂7週齢、経口投与
投与溶媒:5% アラビアゴム
化合物投与量:100 mg / kg
分析試料:下大静脈から採血後の血漿
化合物1及び2について、tau蛋白質のリン酸化に対する抑制活性を実施例1と同様に評価した。その結果の一例を図4に示す。
図4は、図に示す濃度(0.3〜10μM)の化合物存在下でtau蛋白質及びDYRK1A蛋白質の双方を発現誘導した前記培養細胞について、tau蛋白質の212番目のトレオニン残基のリン酸化を特異的に認識する抗体を用いたウエスタンブロッティングを行った結果の一例を示す。なお、「control」は、化合物を加えない場合の結果を示す。図4に示すとおり、化合物1及び2は、強力なtau蛋白質リン酸化抑制効果を示した。なお、in vitroでのDYRK1A阻害能(IC50)は、化合物1が49nM、化合物2が40nMであった。
化合物1及び2について、脳内におけるtau蛋白質のリン酸化に対する抑制活性を評価した。マウスにストレス(氷冷水中で水浴、5分間)を与えることでtau蛋白質のリン酸化を誘導する系を用いた。その結果の一例を図5に示す。
図5は、ストレス負荷の前に予め化合物を投薬し(100mg/kg)、ストレス負荷の後に脳組織を摘出し、western-blotで評価した結果の一例である。図5に示すとおり、ストレス誘導時におけるtau蛋白質のリン酸化が、化合物1及び2で抑制可能であることがin vivoで確認された。
化合物1及び2について、下記条件で経口吸収性と脳内移行性を評価した。その結果の一例を図6及び表1に示す。
[脳内移行性評価条件]
使用動物:ICR マウス ♂7週齢、経口投与
投与溶媒:0.5% カルボキシメチルセルロース
化合物投与量:100 mg / kg
分析試料:下大静脈から採血後の血漿及び脳組織
図6及び表1は、化合物1及び2の経口投与後の血漿中濃度及び脳組織内濃度を測定した結果の一例である。図6及び表1に示すとおり、化合物1及び2について、経口吸収性が認められ、かつ、脳内移行性が確認された。
化合物3、6、9〜15について、tau蛋白質のリン酸化に対する抑制活性を実験例1と同様に評価した。その結果の一例を図7〜9に示す。図7には化合物6、15及び9の結果を、図8には化合物3,11及び12の結果を、図9には化合物13、14及び10の結果の一例をそれぞれ示す。図7〜9に示されるように、化合物3、6、9〜15の化合物は、tau蛋白質リン酸化抑制効果を示した。
ダウン症由来の急性巨核芽球性白血病(AMKL)細胞に対する化合物1〜3、6、9及び15の増殖抑制効果を評価した。具体的には、24ウェルプレートに細胞を播種し、所定濃度の化合物を添加し、5日間培養後、Alamar blue を用いた蛍光強度による検出により細胞数を算出した。なお、化合物を含む培地は、毎日交換した。その結果の一例を図10〜12に示す。図10は、ダウン症由来の急性巨核芽球性白血病(AMKL)細胞CMK11-5に対する増殖抑制効果の結果の一例である。図10に示されるように、全ての評価化合物において優れたがん細胞増殖抑制効果が認められた。図11は、ダウン症由来の急性巨核芽球性白血病(AMKL)細胞J425に対する増殖抑制効果の結果の一例である。図11に示されるように、特に化合物1〜3、6、9において優れたがん細胞増殖抑制効果が認められた。図12は、ダウン症由来の急性巨核芽球性白血病(AMKL)細胞KPAM1に対する増殖抑制効果の結果の一例である。図12に示されるように、特に化合物3において優れたがん細胞増殖抑制効果が認められた。
Retinoblastoma(網膜芽細胞腫)細胞株WERIに対する化合物1〜3、6,9及び15の増殖抑制効果を実験例8と同様に評価した。その結果の一例を図13に示す。図13に示されるように、特に化合物1及び3においてがん細胞増殖抑制効果が認められた。
ヒト肺腺癌由来細胞株(PC-9)に対する化合物2、3、11及び12の増殖抑制効果を実験例8と同様におこない、その結果の培養細胞を顕微鏡観察した。それら結果を図14〜16に示す。図14はPC-9株、図15はPC-9を基としたEGFR inhibitor(gefitinib)-resistant sub- linesであるPC-9-GR-step株、図16はPC-9-GR-high株の結果の一例である。図14〜16に示すとおり、特に化合物3、12はがん細胞に対して優れた細胞死誘導活性を示した。
ヒト乳癌細胞(triple-negative)の2種類の細胞株(MDA-MB-453及びMDA-MB-468)に対する化合物3、6、9及び15の増殖抑制効果を実験例8と同様に評価するのに加え、対象の細胞を細胞接着させないで培養した場合の効果を併せて確認した。MDA-MB-453の結果を図17に、MDA-MB-468を図18に示す。図17及び18に示すとおり、特に化合物3及び化合物15は足場非依存的な増殖抑制効果を示した。
化合物2について、記憶・学習障害是正作用を評価した。本評価では、マウスの脳室内にamyloid-βペプチドを投与し、記憶・学習障害を誘発する評価系を用いた(Maurice et al., 1996)。マウスはSwiss mouse 6週齡 ♂ を用い、各群n=12で試験を行った。amyloid-βペプチド(25-35、配列:Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met)、もしくはコントロールペプチドであるscrambled amyloid-β(25-35、配列:Ala-Lys-Ile-Gly-Asn-Ser-Ile-Gly-Leu-Met-Gly)を蒸留水で溶解し、溶解したそれぞれのペプチド溶液を37度で4日間インキュベートした。
その結果の一例を図19に示す。
Claims (20)
- 下記一般式(I)で表される化合物又はその製薬上許容される塩。
-
- 下記一般式(III)で表される化合物又はその製薬上許容される塩。
-
- 請求項1から4のいずれかに記載の化合物又はその製薬上許容される塩を有効成分として含有する、医薬組成物。
- 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療のための医薬組成物であって、請求項1から4のいずれかに記載の化合物又はその製薬上許容される塩を有効成分として含有する、医薬組成物。
- 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療のための請求項1から4のいずれかに記載の化合物又はその製薬上許容される塩。
- 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療のための医薬組成物を製造するための請求項1から4のいずれかに記載の化合物又はその製薬上許容される塩の使用。
- 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療の方法であって、下記一般式(I)で表される化合物又はその製薬上許容される塩を対象(但し、ヒトを除く)に投与することを含む、方法。
- 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療の方法であって、
- 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療の方法であって、下記一般式(III)で表される化合物又はその製薬上許容される塩を対象(但し、ヒトを除く)に投与することを含む、方法。
- 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療の方法であって、
- 下記一般式(II)で表される化合物又はその製薬上許容される塩を有効成分として含有する、医薬組成物。
-
- 下記一般式(II)で表される化合物(但し、
-
- 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療のための、請求項13又は14に記載の医薬組成物。
- 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療のための医薬組成物を製造するための、請求項13又は14で定義される化合物又はその製薬上許容される塩の使用。
- 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療の方法であって、下記一般式(II)で表される化合物又はその製薬上許容される塩を対象(但し、ヒトを除く)に投与することを含む、方法。
- 精神神経疾患又は悪性腫瘍の予防、改善、進行抑制、及び/又は、治療の方法であって、
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012168850 | 2012-07-30 | ||
JP2012168850 | 2012-07-30 | ||
PCT/JP2013/070636 WO2014021337A1 (ja) | 2012-07-30 | 2013-07-30 | 精神神経疾患又は悪性腫瘍に関する化合物及び医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP5910976B2 true JP5910976B2 (ja) | 2016-04-27 |
JPWO2014021337A1 JPWO2014021337A1 (ja) | 2016-07-21 |
Family
ID=50028010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014528176A Active JP5910976B2 (ja) | 2012-07-30 | 2013-07-30 | 精神神経疾患又は悪性腫瘍に関する化合物及び医薬組成物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US9745323B2 (ja) |
EP (1) | EP2881397B1 (ja) |
JP (1) | JP5910976B2 (ja) |
CN (2) | CN104520303B (ja) |
AU (1) | AU2013297476B2 (ja) |
CA (2) | CA3006139C (ja) |
ES (1) | ES2820553T3 (ja) |
WO (1) | WO2014021337A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015107945A (ja) * | 2013-12-05 | 2015-06-11 | 国立大学法人京都大学 | 神経新生に関する化合物及び医薬組成物 |
CN110312528B (zh) * | 2017-02-20 | 2022-02-18 | 国立大学法人京都大学 | 用于起因于剪接异常的遗传性疾病的药物组合物及治疗方法 |
CN109338402A (zh) * | 2018-11-29 | 2019-02-15 | 福建医科大学 | 一种水中电催化苯并硫代酰胺类化合物合成苯并噻唑的方法 |
KR102491260B1 (ko) * | 2019-12-26 | 2023-01-27 | 연세대학교 산학협력단 | 피롤리딘 유도체 및 이를 포함하는 베타-아밀로이드 또는 타우 단백질 관련 질병의 예방 또는 치료용 약학 조성물 |
JPWO2022255411A1 (ja) | 2021-06-01 | 2022-12-08 | ||
WO2023008470A1 (ja) * | 2021-07-28 | 2023-02-02 | 住友ファーマ株式会社 | 縮環アミン誘導体 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050171026A1 (en) * | 2004-01-09 | 2005-08-04 | Tokyo Medical And Dental University | Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction |
JP2007500171A (ja) * | 2003-07-28 | 2007-01-11 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | Pi3キナーゼ阻害剤として使用するための2−イミノ−4−(チオ)オキソ−5−ポリシクロビニルアゾリン類 |
JP2009528383A (ja) * | 2006-03-02 | 2009-08-06 | スミスクライン・ビーチャム・コーポレイション | Pi3キナーゼ阻害剤として用いるためのチアゾロン |
WO2010010797A1 (ja) * | 2008-07-23 | 2010-01-28 | 株式会社キノファーマ | Dyrkを阻害する化合物を含有する医薬組成物 |
JP2010535180A (ja) * | 2007-08-01 | 2010-11-18 | ユニヴェルシテ ドゥ レンヌ 1 | イミダゾロン誘導体、その調製方法およびその生物学的使用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4782564B2 (ja) * | 2002-07-10 | 2011-09-28 | メルク セローノ ソシエテ アノニム | アゾリジノン−ビニル縮合−ベンゼン誘導体 |
OA12963A (en) * | 2002-11-22 | 2006-10-13 | Smithkline Beecham Corp | Novel chemical compounds. |
JP2010529032A (ja) * | 2007-06-01 | 2010-08-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 治療方法 |
WO2012065139A2 (en) * | 2010-11-11 | 2012-05-18 | Board Of Regents, The University Of Texas System | Entpd5 inhibitors |
-
2013
- 2013-07-30 CA CA3006139A patent/CA3006139C/en active Active
- 2013-07-30 EP EP13825401.6A patent/EP2881397B1/en active Active
- 2013-07-30 CA CA2880487A patent/CA2880487C/en active Active
- 2013-07-30 US US14/418,342 patent/US9745323B2/en active Active
- 2013-07-30 AU AU2013297476A patent/AU2013297476B2/en active Active
- 2013-07-30 ES ES13825401T patent/ES2820553T3/es active Active
- 2013-07-30 WO PCT/JP2013/070636 patent/WO2014021337A1/ja active Application Filing
- 2013-07-30 CN CN201380040385.8A patent/CN104520303B/zh active Active
- 2013-07-30 JP JP2014528176A patent/JP5910976B2/ja active Active
- 2013-07-30 CN CN201710156196.7A patent/CN106986865B/zh active Active
-
2017
- 2017-07-26 US US15/660,364 patent/US10017524B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007500171A (ja) * | 2003-07-28 | 2007-01-11 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | Pi3キナーゼ阻害剤として使用するための2−イミノ−4−(チオ)オキソ−5−ポリシクロビニルアゾリン類 |
US20050171026A1 (en) * | 2004-01-09 | 2005-08-04 | Tokyo Medical And Dental University | Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction |
JP2009528383A (ja) * | 2006-03-02 | 2009-08-06 | スミスクライン・ビーチャム・コーポレイション | Pi3キナーゼ阻害剤として用いるためのチアゾロン |
JP2010535180A (ja) * | 2007-08-01 | 2010-11-18 | ユニヴェルシテ ドゥ レンヌ 1 | イミダゾロン誘導体、その調製方法およびその生物学的使用 |
WO2010010797A1 (ja) * | 2008-07-23 | 2010-01-28 | 株式会社キノファーマ | Dyrkを阻害する化合物を含有する医薬組成物 |
Non-Patent Citations (2)
Title |
---|
JPN6013054527; MURAKI, Michiko et al.: 'Manipulation of alternative splicing by a newly developed inhibitor of Clks' Journal of Biological Chemistry vol.279, no.23, 20040308, p.24246-24254 * |
JPN6013054530; JANUSZ, John M. et al.: 'New Cyclooxygenase-2/5-Lipoxygenase Inhibitors. 3. 7-tert-Butyl-2,3-dihydro-3,3-dimethylbenzofuran D' Journal of Medicinal Chemistry vol.41, no.18, 19980805, p.3515-3529 * |
Also Published As
Publication number | Publication date |
---|---|
CA3006139A1 (en) | 2014-02-06 |
ES2820553T3 (es) | 2021-04-21 |
JPWO2014021337A1 (ja) | 2016-07-21 |
US20150225421A1 (en) | 2015-08-13 |
CA2880487C (en) | 2018-07-24 |
CN104520303B (zh) | 2017-04-12 |
CN106986865A (zh) | 2017-07-28 |
US9745323B2 (en) | 2017-08-29 |
CN106986865B (zh) | 2020-02-28 |
CN104520303A (zh) | 2015-04-15 |
AU2013297476A1 (en) | 2015-02-26 |
CA2880487A1 (en) | 2014-02-06 |
AU2013297476B2 (en) | 2016-05-26 |
EP2881397A4 (en) | 2016-04-06 |
US10017524B2 (en) | 2018-07-10 |
CA3006139C (en) | 2020-06-02 |
WO2014021337A1 (ja) | 2014-02-06 |
EP2881397B1 (en) | 2020-09-02 |
US20170355715A1 (en) | 2017-12-14 |
EP2881397A1 (en) | 2015-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10017524B2 (en) | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | |
JP6856543B2 (ja) | ブロモドメイン阻害剤 | |
US11053207B2 (en) | Indoleamine-2,3-dioxygenase inhibitor and preparation method therefor | |
JP6457623B2 (ja) | 2,4−二置換7H−ピロロ[2,3−d]ピリミジン誘導体、その製造方法および医薬における使用 | |
RU2686323C2 (ru) | Новые соединения и композиции для ингибирования fasn | |
JP6211509B2 (ja) | 複素環化合物およびその用途 | |
AU2016323305A1 (en) | Hepatitis B core protein modulators | |
WO2015083750A1 (ja) | 神経新生に関する化合物及び医薬組成物 | |
KR20170031097A (ko) | 항암제로서 작용화되고 치환된 인돌 | |
JPWO2010074193A1 (ja) | 新規2環性複素環化合物 | |
JP2007015928A (ja) | 新規オレフィン誘導体 | |
KR20160138136A (ko) | 티에노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 백혈병 치료 및 예방용 약학 조성물 | |
JP2014510055A (ja) | ホスホジエステラーゼ10(pde10a)阻害剤としての置換6,7−ジアルコキシ−3−イソキノリノール誘導体 | |
JP2021121599A (ja) | ヒストンデメチラーゼ阻害剤 | |
US9062061B2 (en) | Compound having PARP inhibitory activity | |
JP5667934B2 (ja) | 新規2環性複素環化合物からなる医薬 | |
KR102205619B1 (ko) | 신규한 인다졸 유도체 화합물 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 | |
JP2018087173A (ja) | 悪性脳腫瘍治療薬 | |
CN110066271B (zh) | 吡咯衍生物、其制备方法、药物组合物及应用 | |
JP2016216446A (ja) | ピロリジン−2,5−ジオン誘導体の多形形態、医薬組成物、およびido1阻害薬としての使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20141226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150227 |
|
AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20150303 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150316 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150915 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160128 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160223 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160318 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5910976 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |